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DHHC5 REGULATES BETA-ADRENERGIC SIGNALING IN THE HEART 
THROUGH PALMITOYLATION OF G ALPHA PROTEINS  
 
(Jessica) Jie Chen, B.A. 
 
Advisory Professor: Darren Boehning, Ph.D. 
 
S-palmitoylation is a reversible posttranslational modification that plays an 
important role in regulating protein localization, trafficking, and stability. Recent 
studies have shown that some proteins undergo extremely rapid 
palmitoylation/depalmitoylation cycles after cellular stimulation supporting a direct 
signaling role for this posttranslational modification. The work in this dissertation 
investigated whether β-adrenergic stimulation led to stimulus-dependent 
palmitoylation of downstream signaling proteins in immortalized and primary cell 
models. I found that β-adrenergic stimulation led to rapidly increased Gαs and 
Gαi palmitoylation only in primary cardiomyocytes. The kinetics of palmitoylation 
was temporally consistent with the downstream production of cAMP and 
contractile responses. I identified the plasma membrane-localized palmitoyl 
acyltransferase DHHC5 as an important mediator of the stimulus-dependent 
palmitoylation in cardiomyocytes. Knockdown of DHHC5 showed that this 
enzyme is necessary for palmitoylation of Gαs, Gαi, and functional responses 
downstream of β-adrenergic stimulation. A palmitoylation assay with purified 
components revealed that Gαs and Gαi are direct substrates of DHHC5. Finally, 
 ix 
we provided evidence that the C-terminal tail of DHHC5 can be palmitoylated in 
response to stimulation and such modification is important for its dynamic 
localization in the plasma membrane. My results reveal that DHHC5 is a central 
regulator of signaling downstream of β-adrenergic receptors in cardiomyocytes. 
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Chapter I: Introduction 
 
This chapter is partially based upon a review article originally published in 
 
Chen, J. J., & Boehning, D. (2017). Protein lipidation as a regulator of apoptotic 
calcium release: Relevance to cancer. Frontiers in oncology, 7, 138. 
 
Lipidations and their enzymatic regulators 
Protein lipidation is the cotranslational or posttranslational covalent 
addition of a variety of lipids, including fatty acids, isoprenoids and cholesterol, to 
target proteins (Table 1). Lipidation can be categorized into two types based on 
the location of the modified proteins: those that are modified in the endoplasmic 
reticulum (ER) lumen and secreted, and those that are modified in the cytoplasm 
or on the cytoplasmic face of membrane [1]. The former type includes 
glycosylphosphatidylinositol (GPI) anchor and cholesterylation, and the latter 
type includes N-myristoylation, acylation, and prenylation.  
GPI anchor was first discovered in the parasite Trypanosoma brucei 
where the highly expressed variant surface glycoprotein (VSG) is anchored to the 
cell surface via a glycolipid containing phosphatidylinositol [2-4]. Since then, 
many proteins in mammals and lower eukaryotes such as protozoa have been 
shown to contain GPI anchors with enormous structural variety, most of which 
include an ethanolamine attached to the carboxyl terminus of the protein, a 
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glycan core, inositol, and lipid moieties [5-7]. GPI-anchored peptides often 
include a cleavable N-terminal signal sequence, which directs the peptide to the 
ER lumen, and a hydrophobic C terminal sequence that is cleaved at the time of 
GPI anchor addition [6, 8, 9]. GPI anchors facilitate tethering of proteins to the 
extracellular face of the plasma membrane and are important for many cellular 
functions, including adhesion, membrane trafficking and immune system 
signaling [10-12].  
The GPI precursor, formed in the ER lumen, is transferred to target 
proteins by GPI transamidase, a membrane-bound multi-subunit enzyme [13-16]. 
GPI transamidase cleaves the C-terminal signal peptide of the target proteins, 
and forms an enzyme-substrate intermediate, allowing the nucleophilic attack by 
the terminal amino group of the preformed GPI [17]. 
Cholesterylation is a characteristic of the mammalian Hedgehog family 
proteins, which are secreted signaling proteins that regulate embryonic 
patterning of many tissues and structures [18, 19]. The Hedgehog protein 
undergoes an autocatalytic processing that internally cleaves between the 
conserved Gly257 and Cys258 at the GCF motif, and yields a ~20kD N-terminal 
signaling domain and a ~25kD C-terminal catalytic domain [20, 21]. The N-
terminal domain receives a cholesterol moiety and is active in signaling [19, 21, 
22]. Interestingly, multiple studies have detected other potentially cholesterylated 
proteins [19, 23]. However, the identification of these potential cholesterylation 
targets remains to be elucidated. Cholesterylation of the N-terminal signaling 
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domain of Hedgehog seems to be only dependent on the presence of the C-
terminal catalytic domain, suggesting that this process is autocatalytic [19]. 
N-myristoylation is the attachment of the 14-carbon myristic acid to a N-
terminal Gly residue via an amide bond [24]. It was first identified as a blocking 
group that prevents Edman degradation on the N-terminus of the catalytic 
subunit of cyclic AMP-dependent protein kinase and the calcium-binding β-
subunit of calcineurin [25, 26]. Many other proteins regulating key signaling 
pathways, including the Src family non-receptor protein tyrosine kinases [27, 28] 
and Gα proteins [29, 30] were shown to be myristoylated. These proteins contain 
the N-terminal sequence Met-Gly- and often have a Ser/Thr/Cys at position 6 [24, 
31]. Myristoylation can happen cotranslationally following the removal of the 
initiator methionine residue [32]. Although myristoylation is required for 
membrane targeting of many proteins, it is not sufficient for stable membrane 
anchoring due to its weak hydrophobic nature and often needs subsequent lipid 
modifications [33-35]. Additionally, myristoylation can also happen 
posttranslationally during apoptosis following the caspase cleavage of substrate 
proteins that exposes an internal glycine [36-39]. Many apoptotic proteins, 
including Bid, gelsolin and p21-activated kinase 2, require posttranslational 
myristoylation following caspase cleavage for proper subcellular localization and 
subsequent functions [36-38].  
N-myristoylation is catalyzed by N-myristoyltransferases (NMTs) [40-42]. 
NMTs bind first to myristoyl-CoA and then to the peptide, followed by a direct 
nucleophilic addition-elimination reaction and subsequent release of CoA and the 
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myristoylated peptide [43]. Studies in various tissues and cell types have shown 
that the enzymatic activity of NMTs is predominantly distributed in the cytosolic 
fraction [44-47]. Some studies have shown that low levels of myristoyl-CoA may 
be rate limiting for NMT activity [48, 49]. However, the transcriptional up-
regulation of NMTs under pathological conditions suggests that this might not 
always be the case [50]. 
Acylation is the addition of various fatty acids, such as palmitic acid, oleic 
acid and stearic acid, on different amino acid residues [51-53]. One of the best-
studied types of acylation is S-palmitoylation, which is characterized by the 
reversible addition of the 16-carbon saturated palmitic acid to Cys residues via 
labile thioester bonds [53, 54]. Despite the presence of multiple algorithms to 
predict palmitoylation sites, there is no validated consensus sequence for 
palmitoylation [55-57]. One key aspect of palmitoylation is that its reversibility 
allows for a palmitoylation and depalmitoylation cycle that regulates the 
posttranslational trafficking and functions of target proteins, such as H- and N-
Ras [58]. Palmitoylation can also occur on large transmembrane proteins, 
including ion channels and G protein coupled receptors [59-63]. The roles of 
transmembrane protein palmitoylation include regulation of channel 
maturation/quality control and association with lipid rafts [64-67]. 
Protein S-acylation is regulated by palmitoyl acyltransferases (PATs) and 
acyl-protein thioesterases, which add and remove the lipid group, respectively. 
There are 23 PATs in mammals, all of which share a common DHHC (Asp-His-
His-Cys) motif within a cysteine rich domain [68, 69]. PATs are polytopic 
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membrane proteins that are localized to distinct subcellular compartments, 
primarily the Golgi apparatus and the plasma membrane [70]. Some DHHC 
enzymes show preference for certain types of proteins (i.e. transmembrane 
proteins), and in some cases the same substrates can be palmitoylated by 
multiple DHHC enzymes [68, 71-73]. Compared to the large amount of studies 
on PATs, thioesterases are relatively poorly characterized. Two protein palmitoyl 
thioesterases (PPT1/2) and two acyl protein thioesterases (APT1/2) have been 
identified [74-77]. PPTs predominantly localize to the lysosomal lumen and are 
involved in depalmitoylation during protein degradation, whereas APTs have 
cytosolic localization and are shown to depalmitoylate and recycle signaling 
proteins such as Ras and growth associate protein (GAP-43) from the plasma 
membrane back to Golgi [75-78]. Very recently, two independent groups found 
that the α/β-hydrolase domain (ABHD) family of serine hydrolases are potent 
depalmitoylating enzymes for select substrates, including PSD-95 and N-Ras 
[79, 80]. 
Prenylation is the addition of the 15-carbon farnesyl or the 20-carbon 
geranylgeranyl isoprenoid lipid on cysteine residues via stable thioether bonds 
[81, 82]. It requires a C-terminal CAAX motif, where C is a cysteine, A is aliphatic 
amino acids and X can be any amino acid. Prenylation at the CAAX motif is 
found in many proteins, including mammalian Ras proteins [83, 84]. In addition to 
its role in membrane association, prenylation can also regulate protein-protein 
interactions and subcellular distribution of the modified targets [85, 86]. 
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Prenylation is catalyzed by the enzymes farnesyltransferase (FTase), 
geranylgeranyltransferase I (GGTase 1), and Rab geranylgeranyltransferase 
(GGTase 2) [87-89]. The prenylating enzymes localize to the cytosol and 
conjugate isoprenoids generated from the mevalonate/HMG-CoA reductase 
pathway to target proteins. Specifically, the isoprenoids farnesyl and 
geranylgeranyl are transferred to a C-terminal CAAX motif on target proteins. 
Unlike FTase and GGTase 1, geranylgeranyl transfer by GGTase 2 requires the 
co-factor REP (Rab escort protein) [90]. GGTase 1 and FTase generally have 
high specificity for the protein targets, depending on the X residue [91-93]. 
However, they can act on each other’s substrates. One example is that K-Ras 
and N-Ras, usually targets of FTase, can be geranylgeranylated in Ras-mutant 
human cancer cells treated with FTase inhibitors [94, 95]. Removal of the –AAX 
tripeptide and methylation of the prenyl-cysteine, catalyzed by the ER membrane 
proteins RCE1 and ICMT, respectively, are two post-prenylation steps required 
for maturation of prenylated proteins [96-98].  
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Table 1. Summary of Different Types of Lipidation.  
The lipid moiety structures, effects on target proteins, and enzymatic regulators 
of various lipidation. This table is from Chen, J. J., & Boehning, D. (2017). Protein 
lipidation as a regulator of apoptotic calcium release: Relevance to 
cancer. Frontiers in oncology, 7, 138. Copyrights remain with the authors. 
  
Lipid Structure Effects on proteins Enzymatic regulators
GPI anchor
Plasma membrane 
tethering,
Incorporation into specific
membrane domains,
Protein-protein interaction
Cholesterylation
Myristoylation
Palmitoylation
Farnesylation
Geranylgeranylation
Hedgehog signaling 
activation
Membrane localization,
Autoinhibition
Plasma membrane 
localization,
Partitioning into lipid rafts,
Protein maturation/quality
control
Membrane localization
Conformational change
Protein-protein interaction
Membrane localization
Protein-protein interaction
GPI transamidase
Autocatalytic 
N-myristoyltransferases 
Palmitoyl 
acyltransferases,
Acyl protein 
thioesterases,
α/β-hydrolase fold 
family proteins 
Farnesyltransferase 
Geranylgeranyl
-transferase 
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Palmitoylation and signaling transduction 
 S-Acylation, more commonly known as S-palmitoylation, is the only 
reversible lipidation and therefore its roles in signaling transduction have been 
studied extensively. Recent advances in detecting lipidated proteins by proteomic 
and targeted approaches have revealed that lipidation of signaling proteins is 
essential for regulating a wide variety of signaling pathways. 
 One of the earliest studies reporting S-palmitoylation in mammalian cells 
relies on the incorporation of radiolabeled fatty acid [3H]palmitate into live cells, 
followed by fluorography with long exposure (multiple days) [99]. To detect 
palmitoylation of specific proteins of interest, either purified proteins are needed 
for cell-free labeling with [3H]palmitate, or exposing cells to [3H]palmitate for 
extended period of time is needed [100-102]. While these methods have been 
used to identify various palmitoylation targets, they have many drawbacks. Other 
than the potential health hazard and the time-consuming autoradiograph 
exposure step, the sensitivity and the efficiency of radiolabeling are extremely 
low for some proteins [103].  
 Click chemistry based chemical probes are developed as an alternative to 
better detect protein palmitoylation (Figure 1A) [104]. Synthetic fatty acid 
analogues with alkyne groups at the terminal end furthest away from the carboxyl 
group (ω-position) are incorporated into live cells [105]. Cells are then fixed (for 
fluorescence imaging) or lysed (for biochemical assays), followed by a copper(I)-
catalyzed reaction with azide-conjugated fluorescent groups or biotin for 
detection [106]. Notably, synthetic fatty acids with different chain lengths are 
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shown to incorporate onto proteins via thioester linkage with different efficiency, 
suggesting that while palmitoylation is the most commonly studied S-acylation, 
other lipid groups can be added [104]. Click chemistry based probes are 
especially useful in studies that distinguish the selectivity of different fatty acid 
groups [107].  
 While click chemistry has led to many important discoveries in protein 
palmitoylation (reviewed in [108]), the efficiency of incorporating alkyne 
conjugated probes onto substrates vary, and thus is not suitable for unbiased 
proteomic studies in native tissues. Recently acyl-biotin exchange (ABE, Figure 
1B) has been developed to detect S-acylated proteins in various tissues and 
organisms [71, 109, 110]. The first step of ABE is blocking the free cysteine sites 
on proteins using the thioreactive compound N-ethylmaleimide (NEM) or methyl 
methanethiosulphonate (MMTS). Then the labile thioester bonds at the 
palmitoylated cysteines are cleaved using hydroxylamine (HA, neutral PH), 
exposing the free thiol groups that can be subsequently biotinylated. After 
biotinylation, proteins are pulled down using streptavidin beads and eluted.  
Standard Western blotting can be used to detect the palmitoylation levels of 
proteins of interest [103], or mass spectrometry can be used for global proteomic 
analysis [71]. 
 Acyl-resin-assisted capture (Acyl-RAC, Figure 1B) is a recently developed 
approach similar to ABE. Instead of using biotin conjugation and streptavidin pull-
down, thioreactive Sepharose resin were used after the HA cleavage step [111]. 
This method reduces the length of the procedure and is shown to have improved 
 10 
sensitivity for detecting some palmitoylated proteins while missing some other 
proteins detected by ABE [112].  
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Figure 1 Schematics of methods to detect protein palmitoylation.  
 (A) ω-alkynyl fatty acid is incorporated into live cells, followed by click chemistry 
to detect palmitoylation using azide-conjugated fluorophore (green) or 
biotin/streptavidin-HRP (yellow). (B) Procedures of using acyl-biotin exchange 
(ABE) and acyl-resin-assisted capture (Acyl-RAC) to study the palmitoyl 
proteome or proteins of interest.  
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Due to the proliferation of targeted and proteomic studies using click 
chemistry based probes, ABE, or Acyl-RAC to identify fatty acylated proteins, 
protein palmitoylation is shown to play central roles in various signaling pathways 
[105]. Our group [113] and others [114-117] have investigated the role of 
palmitoylation in regulating death receptor signaling. We found that components 
of the T cell receptor (TCR) complex such at Lck, Zap-70, PLC-γ1, and other 
TCR components were required for apoptotic calcium release in T cells after 
engagement of the Fas receptor with Fas ligand [118]. The Src kinase Lck is 
myristoylated and doubly palmitoylated on the N-terminus, and these 
modifications regulate its plasma membrane localization and partitioning into lipid 
rafts. It is known that the Fas macromolecular complex assembles and signals in 
lipid rafts [119], so we asked whether Fas stimulation resulted in rapid 
palmitoylation of Lck. Fas stimulation resulted in a rapid increase in de novo 
palmitoylation of Lck detectable within minutes of Fas receptor engagement 
[113]. Surprisingly, after longer period of stimulation (>10 min) of the Fas 
receptor, Lck palmitoylation levels rapidly decreased to even lower than the 
levels seen in non-stimulated cells. Importantly, the rapid but transient increase 
in palmitoylation of Lck closely matched the activation kinetics of signaling 
proteins involved in the initiation of Fas receptor signaling [113]. We therefore 
proposed that the enzymatic mechanisms controlling stimulus-dependent protein 
palmitoylation and depalmitoylation likely are directly activated by components of 
the Fas signaling pathway. In the case of Fas signaling, the plasma membrane 
localized DHHC21 protein is essential [113]. Presumably Fas stimulation rapidly 
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activates DHHC21 and a yet unidentified acyl-protein thioesterase to regulate 
Lck lipidation levels. How the activation of these enzymes occurs is unknown, but 
could possibly be regulated either directly or indirectly by calcium ions (Ca2+). 
In order to better understand the role of stimulus-dependent rapid 
palmitoylation and their roles in signaling transduction, it is worthwhile to consider 
the kinetics of the enzymatic machinery. Over 15 years ago it was shown that β-
AR stimulation resulted in rapid turnover of the palmitoylation [120, 121] and 
depalmitoylation [122] cycle of Gαs. The model was based upon availability of 
free Gαs: dissociation from the βγ subunits allowed putative palmitoylating and 
depalmitoylating enzymes access to the protein. However, a later study found 
that stimulation of beta-adrenergic receptors (β-ARs) in kidney fibroblast-like 
COS cells and S49 lymphoma cells did not lead to detectable changes in Gα 
protein palmitoylation levels using high performance liquid chromatography 
(HPLC) [123]. Since then, other proteins such as PSD-95, eNOS, and Ras have 
been shown to have increased turnover of palmitoyl groups in response to 
various stimuli, suggesting rapid cycling of lipids in various signaling cascades 
[124]. However, further studies on the rapid palmitoylation of endogenous 
proteins and their downstream functional roles are still needed, especially in 
specific cell types including cardiac cells. 
 
Beta-adrenergic signaling in cardiomyocytes 
 One of the most well studied pathways in the heart is the β-AR signaling 
pathway. Drugs that block the activation of this pathway, termed beta-blockers, 
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are among the most commonly used medications for pathological conditions 
such as heart failure [125, 126]. Heart failure is the leading cause of death in 
many developed countries such as the United States [127]. The hallmarks of 
heart failure include reduction in response to sympathetic stimulation and thus 
inability to increase cardiac output [128]. One of the key signaling pathways that 
regulate these processes in cardiomyocytes is the β-AR signaling pathway.  
β-ARs are transmembrane G-protein coupled receptors that transmit 
extracellular signals to mediate contractility in the heart. Under conditions where 
organs and tissues have increased demand for oxygen delivery, the sympathetic 
nervous system is activated and neurotransmitters norepinephrine and 
epinephrine are produced [129]. When ligands such as norepinephrine and 
epinephrine bind to the β-ARs, they interact with distinct classes of the 
heterotrimeric G-proteins, consisting of α, β, and γ subunits, and allow for the 
exchange of GDP for GTP [130, 131]. Active Gα and Gβγ subunits then 
dissociate and trigger different downstream signaling events.  
There are two major sub-types of β-ARs in mammalian hearts—β1-AR and 
β2-AR. β1-AR is the predominant type and accounts for 75-80% of cardiac β-ARs, 
whereas β2-AR accounts for 20-25% [132]. Different subtypes of β-ARs can 
couple with distinct subfamilies of G-proteins (Figure 2A). Both β1-AR and β2-AR 
associate with Gαs, which results in activation of downstream adenylyl cyclase 
(AC) and production of cAMP. The primary target of cAMP is protein kinase A 
(PKA), which phosphorylates substrates such as L-type calcium channel (LTCC), 
phospholamban (PLB), ryanodine receptor (RyR), and cardiac troponin I (cTnI) 
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[133]. PKA-mediated phosphorylation of the plasma membrane localized LTCC 
leads to increased Ca2+ uptake into the cell [134]; Phosphorylation of PLB 
reduces its inhibitory effects on sarcoplasmic reticulum calcium ATPase 
(SERCA), which results in increased Ca2+ storage in the sarcoplasmic reticulum 
(SR); RyR phosphorylation leads to increased Ca2+ release from the SR [135]; 
and cTnI phosphorylation leads to altered Ca2+ affinity for the myofilaments and 
cross-bridge kinetics [136]. All of these events result in increased contractility of 
cardiomyocytes, also known as positive inotropy. Positive inotropic effect is 
defined by an increase in muscular contractile forces [137]. The force production 
in cardiomyocytes is dependent on the actin-myosin cross-bridge, which is 
regulated by intracellular Ca2+ levels [138]. The majority of the Ca2+ needed for 
cardiac contraction is released from the SR through a process called calcium-
induced calcium release [139]. Depolarization of the membrane results in the 
opening of LTCC and a small amount of Ca2+ influx, which leads to the opening 
of RyR and large amount of Ca2+ release from the SR (reviewed in [140]). 
Therefore, positive inotropic effects induced by activation of the β-AR signaling 
pathway result in increased intracellular Ca2+ levels.  
In addition to Gαs, β2-ARs also bind to Gαi, which inhibits the AC-cAMP-
PKA pathway [141]. Given the relative low numbers of Gαi-coupled receptors 
compared to Gαs-coupled receptors under normal physiological conditions, the 
overall effect of stimulation by agonists such as isoproterenol (ISO, agonist for 
both β1AR and β2AR) leads to positive inotropic effects [142]. However, β2-ARs 
shift from Gαs coupling to Gαi coupling when phosphorylated by PKA after 
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prolonged stimulation, contributing to desensitization of the pathway [143, 144]. 
Studies in multiple heart failure models observed increased expression and 
receptor coupling of Gαi [145-147]. Additionally, β2-AR stimulation can also 
activate the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol-3’-kinase (PI3K) pathways in a Gαi-dependent fashion and 
has protective effect in cardiomyocytes against apoptosis [148]. Spatial and 
temporal regulations of signaling proteins are important to mediate subtype-
specific responses to β-AR stimulations. In cardiomyocytes, β2-AR, ACs and 
certain PKA subunits are enriched in caveolae, lipid-raft-like structures that form 
invaginations [149]. Caveolae exist in many tissues and their structure is 
dependent on the scaffolding protein caveolin [150, 151]. There are three 
members in the human caveolin gene family and caveolin-3 is specific to muscle 
cell types [152, 153]. Domain mapping studies identified caveolin-binding motifs 
that are present on various signaling proteins downstream of β-ARs, including 
Gα proteins [154, 155]. Caveolae provide the spatial proximity of these upstream 
proteins in the β-AR signaling cascade that favors the efficient and rapid 
recruitment of effectors following receptor activation [149]. Recently, proteomic 
studies revealed that palmitoylated proteins are enriched in caveolae, suggesting 
that palmitoylation is a better predictor of caveolae localization than caveolin 
binding motifs in cardiomyocytes [32]. Therefore, studying stimulus-dependent 
palmitoylation of endogenous proteins is crucial for understanding β-AR signaling 
in cardiomyocytes.  
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Another key aspect of β-AR signaling in the heart is its negative feedback 
via receptor desensitization, which is mediated by the serine/threonine kinases 
G-protein coupled receptor kinases (GRKs, Figure 2B). GRK2 and GRK5 are the 
most abundantly expressed GRK family members in the heart [156, 157]. Both 
GRK2 and GRK5 are crucial players in cardiac pathology. In failing heart, 
increased expression of GRK2 and GRK5 contribute to decreased β-AR 
signaling efficiency and thus disable the contractile function of the heart to meet 
its demand [158, 159]. GRKs phosphorylate the ligand-bound receptors, leading 
to recruitment of β-arrestin and internalization of the receptor [160]. Plasma 
membrane localization of GRKs is crucial for receptor desensitization. 
Interestingly, GRK2 is known to go through isoprenylation, a non-reversible lipid 
modification at the C-terminal CAAX domain, but isoprenylation alone is not 
sufficient for its plasma membrane targeting [161]. Multiple studies have 
demonstrated that GRK2 directly binds the dissociated Gβγ subunits, and the 
formation of the complex is important for its plasma membrane localization and 
functions [162, 163]. Further studies deciphering whether GRK proteins are 
subject to other forms of lipidation in cardiomyocytes are necessary.  
  
 18 
 
Figure 2 Beta-adrenergic signaling pathways in cardiomyocytes 
(A) Agonist stimulation of beta-adrenergic receptors (β-ARs) leads to activation 
of adenylyl cyclase (AC) and production of cAMP. Protein Kinase A (PKA) is 
subsequently activated and phosphorylates L-type calcium channel (LTCC), 
phospholamban (PLB), ryanodine receptor (RyR), and cardiac troponin I (cTnI). 
Lipid subdomain in the plasma membrane is shown in grey. (B) G protein 
coupled receptor kinase (GRK) phosphorylates β-AR, which results in β-arrestin 
binding and receptor internalization.  
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Beta-adrenergic signaling and palmitoylation 
 Many proteins in the β-AR signaling pathway are palmitoylation targets. In 
HEK293 cells overexpressing β1-AR, mutation studies using [3H]palmitate 
showed that β1AR is palmitoylated at Cys 392, 393, and 414 [164]. Loss of 
palmitoylation at these sites did not affect protein stability or plasma membrane 
localization, but only the Cys 414 mutant showed reduced internalization 
following stimulation. Interestingly, click-chemistry based pulse-chase labeling 
showed stable palmitoylation at position 392/393 and fast turnover rate (15 min) 
at position 414, suggesting differential regulation and potentially distinct functions 
of palmitoylation at these sites.  
 β2-AR is one of the first G protein coupled receptors (GPCRs, following 
the light-activated GPCR rhodopsin [59]) to be identified as a palmitoylation 
target. The first reported palmitoylation site on β2-AR is Cys 341, and mutation at 
this site led to reduced downstream cAMP production in the Chinese hamster 
fibroblast cell line CHW-1102 [61]. Later studies showed that loss of Cys 341 
palmitoylation increased receptor phosphorylation level at Ser 345/346 and 
uncoupling from Gαs, a process mediated by PKA [165, 166]. In cardiomyocytes, 
palmitoylation of β2-AR at Cys 341 is crucial for its association with 
phosphodiesterase (PDE) 4D and subsequent β-arrestin mediated internalization 
[167]. Recently, a second palmitoylation site Cys 265 was identified within β2-AR 
by using acyl-RAC [168]. Palmitoylation at Cys 265 is evident after 20 min of ISO 
stimulation and peaks after 120 min. Additionally, this study by Adachi et al. also 
revealed that Golgi-localized DHHC9/14/18 redundantly palmitoylate Cys 265, 
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but not Cys 341. Adachi et al. proposed that palmitoylation at Cys 265 
contributes to preserving β2-ARs at the plasma membrane after sustained 
adrenergic stimulation. However, this study used 2-bromopalmitate (2-BP) and 
palmostatin B (PalmB) to inhibit and enhance palmitoylation of β2-ARs, 
respectively. These methods are not designed for analyzing the functions of 
palmitoylation under physiological conditions. Additionally, 2-BP also inhibit other 
enzymes including APT1, which catalyzes depalmitoylation [169], and therefore 
cannot be used as a reliable way to inhibit palmitoylation.  
 Gα subunits, including the s, i, o, z, and q, are all shown to incorporate 
[3H]palmitate at cysteines near the N-terminus in COS cells or insect Sf9 cells 
[170].  Mutation studies showed that palmitoylation of Gαs, Gαq, and Gαo are 
essential for their membrane association [171, 172]. In addition to plasma 
membrane localization, Gαi and Gαz palmitoylation alters their interaction with 
various regulators of the G protein signaling (RGS) proteins in brain [173]. 
Mutation studies at Cys 3 reported various effects on downstream signaling 
events, including activation of AC [174] and MAPK [175]. As mentioned briefly 
before, stimulation of β-ARs in cells lines led to increased turnover of the 
palmitoylation/depalmitoylation cycle on Gαs [122]. Interestingly, dynamic 
palmitoylation of Gα proteins is not specific to the β-AR signaling pathway. Gαi, 
Gαo, and Gαq had increased palmitoylation turnover upon serotonin receptor 
activation in brain [176].  
 Additionally, GRK proteins are also shown to be palmitoylation targets. 
There are six members in the human GRK gene family [177]. In kidney fibroblast 
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COS-7 cell line, GRK6 was shown to be palmitoylated at three cysteines (561, 
562, and 565) in the C-terminal domain and the palmitoylation targets the protein 
to membrane [178]. Subsequently, all of the four GRK4 isoforms were shown to 
be palmitoylated [179]. Mutation studies in COS cells showed that loss of GRK6 
palmitoylation did not affect its kinase activity, but greatly reduced its ability to 
sequester β2AR following stimulation [180].  
GRK2 and GRK5 are the most abundantly expressed GRK family 
members in the heart [156, 157]. However, neither of them was shown to 
incorporate [3H]palmitate [178]. It is proposed that the basic amino acids at 
position 552-562 near the C-terminal domain of GRK5 are important for its 
association with the membrane [181]. The positive charges from these basic 
amino acids can form electrostatic interaction with the negatively charged lipid 
head groups and stabilize GRK5 at the membrane [179, 182]. Multiple studies 
have demonstrated that GRK2 directly binds the dissociated Gβγ subunits, which 
are isoprenylated, and the formation of the complex is important for its plasma 
membrane localization and functions [162, 163]. Given the recent development in 
methods to detect endogenous protein palmitoylation levels, we are interested in 
identifying the dynamic palmitoylation levels of signaling proteins and their 
functional outcomes in cardiomyocytes.  
 
Palmitoyl acyltransferases and their functions in cardiomyocytes 
 To better understand the role of palmitoylation on signaling transduction in 
cardiomyocytes, it is worth considering the enzymatic regulators that catalyze the 
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attachment of palmitic acid moiety onto substrates. As mentioned briefly in 
previous sections, 23 DHHC (referring to the conserved amino acids at the 
catalytic core) enzymes exist in the human genome [69]. This class of enzymes 
was first discovered in yeast for palmitoylation of Ras [183]. In vitro assays using 
[3H]palmitoyl-CoA revealed that DHHC enzymes are sufficient for the transfer of 
palmitic acid from CoA to target cysteines, and they go through autoacylation, 
presumably at the DHHC site [184]. A later study using DHHC2 and DHHC3 
showed that DHHC autoacylation at the catalytic Cys site serves as an acyl-
enzyme intermediate in a two-step ping-pong mechanism [185]. Recently, the 
crystal structures of zebrafish DHHC15 and human DHHC20 were solved [186]. 
This study revealed that the binding of Zn2+ ions is crucial for positioning the 
catalytic Cys, which is positioned at the protein-lipid interphase, and that the 
transmembrane domains form a hydrophobic pocket where acyl-CoA chains of 
specific lengths can fit [186]. Despite a highly conserved catalytic domain, the 
human DHHC family members display considerable amino acid sequence 
divergence, especially in the C-terminal tail region (reviewed in [187]). The roles 
of DHHC enzymes and their targets have been extensively studied in the context 
of neurological diseases and cancers (reviewed in [188]). However, fewer studies 
were dedicated to their functions in cardiac cells.  
 One of the DHHC enzymes that have been implicated to play a crucial role 
in the heart is DHHC16. DHHC16 deficient mice showed severe birth defects 
including partial embryonic lethality, eye malformation, and cardiomyopathy 
[189]. Zhou et al. identified phospholamban (PLB) as one of the DHHC16 
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substrates and palmitoylation of PLB is crucial for obtaining its quaternary 
structure. Additionally, Zhou et al. found that introducing PLB deficiency into the 
DHHC16 deficiency mice rescued some of the cardiac phenotypes [189]. The 
study by Zhou et al. provided the first evidence that DHHC16 is crucial for heart 
development. However, many questions remain such as what other substrates 
are palmitoylated by DHHC16 in cardiomyocytes? Is there dynamic regulation of 
PLB palmitoylation after activation of the β-AR/AC/PKA pathway? One recent 
study in the HAP1 cell line reported a palmitoylation cascade in which DHHC16 
palmitoylates DHHC6 at three cysteines in the C-terminal SH3 domain [190]. 
This also raises the question of whether the cardiac phenotypes observed in 
DHHC16 mouse model are due to direct effects of DHHC16 or through another 
DHHC enzyme.  
 DHHC5 is one of the best characterized PATs in the heart and 
palmitoylation of its substrate phospholemman (PLM) is crucial for mediating a 
process called massive endocytosis (MEND). PLM is a regulatory subunit of the 
cardiac Na/K pump [191]. PLM can be phosphorylated by PKA and PKC, and 
subsequently activates the Na/K pump [192]. On the other hand, PLM can also 
be palmitoylated to inhibit Na/K pump activity [193]. Co-immunoprecipitation 
experiments showed that DHHC5, along with DHHC 4, 6, and 7, binds PLM. In 
adult rat ventricular myocytes (ARVMs), DHHC2, 4, 5, and 7 are most abundantly 
expressed at the mRNA level [194]. DHHC5 is one of the few PATs that are 
shown to localize at the plasma membrane [70], where its target PLM is located. 
Over-expression and knockdown of DHHC5 enhanced and suppressed, 
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respectively, PLM palmitoylation levels in cell lines. Additionally, the study by 
Howie et al. also identified the PLM palmitoylation site to be at a single Cys in 
ARVM [194]. 
 To further elucidate how DHHC5 potentially affects cellular activities in 
cardiomyocytes, a DHHC5 knockout mouse model was used to study MEND, a 
cellular process that happens during reperfusion of anoxic heart [195] (Figure 3). 
MEND is characterized by internalization of more than 70% of the plasma 
membrane [196]. MEND can be triggered by the release of Coenzyme A (CoA) 
from the mitochondria upon calcium overload and oxidative stress. The presence 
of CoA in the cytoplasm allows the synthesis of Acyl-CoA, which can then be 
used to palmitoylate surface membrane proteins [196]. Interestingly, MEND can 
be promoted by overexpression of palmitoylated PLM [193], providing a potential 
mechanism by which DHHC5-mediated palmitoylation of PLM plays an essential 
role in mediating MEND. Indeed, myocytes isolated from DHHC5 deficient mice 
showed increased Na/K pump activity as well as more surface localized PLM 
[197]. Additionally, MEND is inhibited in post-anoxia reperfusion models in the 
DHHC5 deficient heart [197]. These data suggest that the availability of Acyl-CoA 
can be one potential mechanism by which DHHC5-mediated PLM palmitoylation 
is regulated in cardiomyocytes. Interestingly, both PLM and DHHC5 are shown to 
be enriched in caveolae [194], suggesting that the physical proximity of the 
substrate may be another way to regulate DHHC5-mediated palmitoylation.  
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Figure 3 DHHC5 mediates massive endocytosis in cardiomyocytes 
Increased calcium storage in mitochondria or oxidative stress leads to export of 
Coenzyme A (CoA) through permeability transition pore (PTP) that spans the 
inner and outer mitochondria membranes (IMM and OMM). Palmitoyl-CoA is then 
synthesized and used by DHHC5 to palmitoylate phospholemman (PLM) in the 
presence of reactive oxygen species (ROS). PLM palmitoylation leads to 
massive endocytosis (MEND) and internalization of Na/K pumps.  
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It is worth noting that truncation studies have shown that the C-terminal 
domain between N218 and T334 is crucial for DHHC5 substrate recognition 
[194]. Additionally, emerging evidence has shown that DHHC5 can be 
posttranslationally modified in the C-terminal tail. In neurons, the tyrosine kinase 
Fyn phosphorylates DHHC5 at Y533 and forms a DHHC5/Fyn/PSD-95 protein 
complex to keep them at the synaptic membrane [198]. Proteomic approaches in 
adult mouse forebrain extracts revealed that DHHC5 was found to be 
palmitoylated at three potential cysteines in the C-terminus tail (Cys 236, 237, 
and 245), some of which are conserved in other DHHC enzymes [199]. 
Therefore, further studies are needed to identify post-translational modifications 
of DHHC5 and how they regulate its activities in cardiomyocytes.  
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Chapter II: Material and Methods 
 
This chapter is partially based upon a preprint article: 
 
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) 
The palmitoyl acyltransferases DHHC5 mediates beta-adrenergic 
signaling in the heart by targeting Gα proteins and G protein-coupled 
receptor kinase 2. bioRxiv preprint.	
 
Antibodies, constructs, and reagents 
Mouse monoclonal anti-Gαs was purchased from Millipore (MABN543). Rabbit 
monoclonal anti-Gαi/o and rabbit polyclonal anti-calnexin was purchased from 
Abcam (ab140125, ab22595). Rabbit polyclonal anti-GRK2, anti-PKA C-α, anti-
PKA RI-α/β were purchased from Cell Signaling (#3982, 4782, 3927). Rabbit 
polyclonal anti-AC5/6 was purchased from Millipore (ABS573). Rabbit polyclonal 
anti-DHHC5 was purchased from Proteintech (21324-1-AP). Secondary 
antibodies conjugated to Alexa-488, Alexa-555 (Molecular Probes), peroxidase 
(Jackson ImmunoResaerch), IRDye 680LT, and 800CW (LI-COR) were used. 
The 3xFLAG-DHHC5 construct was a gift of Dr. Yusuke Ohno (Sapporo, Japan). 
DHHS5 mutant was built using q5 mutagenesis kit (NEB) with primers 5’-
TGATCATCACAGCCCCTGGGTG-3’ and 5’-AATTCCTCCACACAGTTGTCAC-
3’. DHHC5 Cys 236 to Cys 245 deletion (DHHC5Δ236-245) mutant was built with 
primers 5’-AGTTCTCCAGCACCCAGG-3’ and 5’- GCCATTGGTGAAGGGATTC-
3’. DHHC5 Cys 236 to Ser (DHHC5C236S) mutant was built with primers 5’-
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CACCAATGGCAGCTGTAACAACG-3’ and 5’-AAGGGATTCACACCTCCC-3’. 
DHHC5 Cys 245 to Ser (DHHC5C245S) mutant was built with primers 5’-
CCGTGTCCTCAGCAGTTCTCCAG-3’ and 5’-CTAACGTTGTTACAGCAGCC-3’. 
DHHC5C236S_C245S double mutant was built using the same primers as 
DHHC5C245S in the DHHC5C236S background. DHHC5 tail-less (DHHC5TL) 
mutant was built with primers 5’-ATTTCATGTGTAACTGGTGGCTAGGGGAC-3’ 
and 5’- CCTGTGAGGCCAGCTACA-3’ so that Val 209 was changed to a stop 
codon. DHHC5 truncation mutant that changes Ser 376 to a stop codon 
(DHHC5S376STOP) was built with primers 5’-
CGCCAAGTTGTGACGTGGAGACA-3’ and 5’-CTGGAGGAATGAGGCATG-3’. 
DHHC5 truncation mutant that changes Ser 584 to a stop codon 
(DHHC5S584STOP) was built with primers 5’- 
CCCCCGTACTTGATCCTCCTCAGATG-3’ and 5’- GCATGGCCTGAGCCTGGT-
3’. DHHC5 was cloned into the pmCherry-C1 Vector from Clontech (632524) 
using the NEBuilder High-Fidelity DNA Assembly Cloning (NEB, E5520) with 
primers 5’-
CGACGGTACCGCGGGCCCGGGATCCATGCCCGCAGAGTCTGGAAAG-3’ 
and 5’-
TCAGTTATCTAGATCCGGTGGATCCTCACACCGAAATCTCATAGGTGG-3’ 
following the manufacturer’s protocol. Isoproterenol was purchased from Tocris 
(#1747) and was prepared fresh before use. Silencer Select DHHC5 siRNAs 
(s168613, s168614) and negative control medium GC duplex siRNA (12935112) 
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were purchased from ThermoFisher Scientific. All other reagents were purchased 
at the highest possible purity from Sigma-Aldrich.  
 
Cell culture 
The rat myoblast H9c2 and HEK293 cell lines were obtained from the American 
Type Culture Collection (ATCC) and maintained according to ATCC guidelines. 
Neonatal rat ventricular cardiomyocytes (NRVMs) were prepared from 1 to 2 day-
old Sprague-Dawley rat pups, as previously described [200]. Animals were 
purchased from Texas Animal Specialties (Humble, TX) and processed on the 
same day. Cardiomyocytes were plated on Primaria polystyrene plates (Corning) 
or fibronectin-coated glass coverslips. Cells were initially maintained in a mixture 
of 40% DMEM, 40% Ham’s F10 culture medium, and 20% FBS. Forty-eight 
hours after plating, the media was replaced by a mixture of 50% DMEM and 50% 
Ham’s F10 culture medium, supplied with human recombinant insulin (Gibco), 
transferrin, and thyroxine (Sigma). Cytosine-B-D-arabino-furanoside 
hydrochloride (10µM, Sigma) was present in all culture medium to prevent 
proliferation of fibroblasts or endothelial cells. Cardiomyocytes were transfected 
with Lipofectamine 3000 following manufacturer’s instruction. All siRNA knock-
down experiments were carried out 48 hours following transfection and within 
one week of initial plating. The vertebrate animal procedures were approved by 
the Animal Welfare Committee (AWC) at UTHealth. For each assay, n represents 
number of biological replicates from separate NRVM preps.  
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Preparation of adult left ventricular lysates 
Frozen left ventricle tissue from adult rats was a gift of Dr. Karmouty-Quintana 
(UTHealth) and Drs. Youker and Amione-Guerra (Houston Methodist Hospital). 
Frozen tissue was homogenized and lysed in 1% β-D-maltoside in PBS, 
supplemented with a protease inhibitor mixture (Roche 11873580001) and the 
acyl protein thioesterases inhibitor ML211 (10µM, Cayman Chemicals), followed 
by centrifugation (8000 xg, 5min) to remove insoluble material. The cleared 
supernatant was stored at -80°C. 
 
Acyl biotin exchange 
NRVMs were plated at a density of 1,000 cells per mm2 on 6-well plates. For 
control and DHHC5 knockdown experiments, the total amount of siRNA 
transfected was 30 pmol per 900,000 cells. NRVMs were stimulated with 10 µM 
ISO at room temperature for indicated times, followed by scraping on ice in ice-
cold lysis buffer. Cells were lysed in 1% β-D-maltoside or 0.5% SDS (for DHHC5 
tail palmitoylation experiments) in PBS, supplemented with a protease inhibitor 
mixture (Roche 11873580001) and acyl protein thioesterases inhibitor ML211 (10 
µM, Cayman Chemicals). Acyl biotin exchange was performed as described 
previously with slight modifications [71]. Briefly, proteins were precipitated by 
choloroform-methanol (CM) and incubated with 10 mM N-ethylmaleimide (NEM) 
overnight at 4°C with gentle mixing. Following three rounds of CM precipitation, 
samples were incubated with 400 mM hydroxylamine (HA, pH=7, freshly 
prepared) and 1 mM HPDP-biotin for 50 min at 37°C with gentle mixing. When a 
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minus-HA treated sample was included, the sample was divided into two equal 
parts after the third precipitation and sodium chloride was used instead of HA. 
After three rounds of CM precipitation, samples were incubated with Streptavidin-
agarose (Pierce) beads for at least 90 min up to 8 hrs at room temperature with 
gentle mixing. Following four rounds of washes, bound proteins were eluted for 
15 min at 80°C with shaking in 30 µl of elution buffer containing 1% β-
mercaptoethanol and 2 mM DTT. The supernatants were transferred to new 
tubes and 20 µl of the samples were loaded onto a 4-20% gradient SDS-PAGE 
gel (BIO-RAD), followed by transfer to nitrocellulose membrane and 
immunoblotting.  
 
cAMP ELISA  
For quantification of intracellular cAMP levels, NRVMs were plated at a density of 
175 cells per mm2 on 24-well plates. For siRNA knockdown experiments, cells 
were transfected with 5 pmol of siRNA for 48 hr. For knockdown and rescue 
experiments, cells were transfected with 5 pmol of siRNA for a total of 48 hr and 
2 µg of DNA were transfected 24 hr after the siRNA transfection. Cells were 
stimulated with 1 µM ISO and assayed using the direct cAMP ELISA kit (Enzo) 
per manufacturer’s instructions. Each well was lysed in 250 µl provided lysis 
buffer by scraping the wells. Final results were analyzed using a Tecan Spark 
Multimode Microplate Reader. Each experiment was performed with at least 
three biological replicates. 
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Calcium imaging 
NRVMs were plated at a density of 300 cells per mm2 on fibronectin-coated glass 
coverslips. Cardiomyocytes were loaded with Fura-2 AM as described previously 
[200]. Briefly, cardiomyocytes were incubated with Fura-2 AM in imaging solution 
(1% BSA, 107mM NaCl, 20 mM HEPES, 2.5 mM MgCl2, 7.5 mMKCl, 11.5mM 
glucose, and 1 mM CaCl2) for 30 min at room temperature. Then cardiomyocytes 
were incubated in imaging solution without Fura-2 AM for 20 min at room 
temperature before mounting onto the microscope. Images were taken on a 
Nikon TiS inverted microscope with a 40X oil immersion objective, and images 
were taken every second with a Photometrics Evolve EMCCD camera. ISO (10 
µM) was added after 2 min of baseline recording. An oscillation was counted 
when the Fura-2 ratio rose 10% above the baseline ratio. Oscillation frequencies 
before and after ISO were calculated from five coverslips for each condition and 
mean ± SEM were plotted as described [200]. 
 
TIRF microscopy and analysis 
NRVMs were plated at a density of 200-250 cells per mm2 on fibronectin-coated 
glass coverslips and transfected with mCherry-DHHC5 or mCherry-DHHC5Δ236-
245 for 24 hrs using Lipofectamine 3000. Images were taken on a Nikon Eclipse 
TiS TIRF microscope with a 60X Apo TIRF oil immersion objective every 500 ms 
with an Andor Zyla sCMOS camera. Beating cardiomyocytes were located and 
imaged for three minutes before treating with ISO (10 µM). Cells were 
continuously imaged for 10 min after stimulation. Images were analyzed using 
the TrackMate v3.8.0 Plugin for Fiji [201]. We used the LoG detector for particles, 
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and the thresholds were determined for each cell based on the fluorescence 
intensity. We used the LAP tracker (max distance 15 pixel, max frame gap 4) for 
particle tracking. All output files from TrackMate were used for data analysis. 
“Links in track statistics” data from each cell was exported from TrackMate as 
comma-separated values (csv) files and analyzed using custom Python scripts 
utilizing the pandas and NumPy packages for data analysis. Tracking files from 
individual cells were merged together into wildtype and mutant data frames. Time 
bins of 30 s were created for the 13-minute experiment duration and each row of 
the data frames, representing 0.5 s, were assigned to these time bins. 
Downstream analyses were carried out using these 30 s time bins. Particle 
lifetime analysis was performed by extracting all particles which existed during a 
30 s bin at the start of the experiment (time 0 min) and during one bin at the end 
of the experiment (time 10 min). The time that a particle existed (in frames) within 
this window was calculated for each particle and the normalized distribution was 
plotted along with the kernel-density-estimate (KDE) of the distribution [202]. 
Plotting was performed in Python using the seaborn and matplotlib packages. 
The mean squared displacement of every particle was calculated in Python using 
the following formula at each frame (n) (0.5s) for a total of 60 frames (N) where x 
and y represent the coordinate position of the particle as determined by 
TrackMate: 
𝑀𝑆𝐷 𝑛 = 1𝑁 − 𝑛 𝑥!!! − 𝑥! ! + 𝑦!!! − 𝑦! !!!!!!!  
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The MSD at each frame was plotted for a 30 s bin immediately prior to treatment 
(frames 300-360) and for a 30 s window 10 minutes post-treatment (frames 
1560-1620). 
 
Immunofluorescence staining 
NRVMs were plated at a density of 250 cells per mm2 on fibronectin-coated glass 
coverslips. Immunofluorescence staining was performed as described previously 
[200]. Briefly, H9c2 or NRVMs were fixed using 100% ice-cold methanol at -20°C 
for 20 min, and permeabilized using 0.1% saponin in PBS at room temperature 
for 10 min. After washing with PBS, samples were blocked in 5% FBS and 1% 
BSA in PBS. Primary antibodies were diluted in the same buffer as blocking. 
Anti-DHHC5 was used at a concentration of 1:100. Secondary antibodies were 
used at a concentration of 1:500. Samples were mounted in VECTASHIELD 
antifade mounting medium with DAPI, sealed, and kept at 4°C. Images were 
taken on a ZEISS Cell Observer SD laser scanning confocal system with a 63x 
oil objective. For the quantification of plasma membrane localization of DHHC5, 
the percentage of cells displaying near plasma membrane localization (example 
shown in Figure 7) from five separate fields was scored in a blinded manner.  
 
In vitro DHHC5 activity assay 
HEK293T cells were not transfected (control) or transfected with FLAG- or 
mCherry- tagged DHHS5 and DHHC5 using Lipofectamine 3000 for 18-24 hrs. 
Cells were lysed in lysis buffer containing 0.5% SDS, 150mM NaCl, 50mM Tris, 
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1% Triton and 1mM EDTA, in the presence of protease inhibitor (Roche). Lysates 
are incubated at 4°C with rotation for 15 min, sonicated until no longer viscous, 
and diluted using lysis buffer to a final concentration of 0.01% SDS. Rabbit 
monoclonal anti-FLAG (CST147935) or RFP-Trap (ChromoTek) were used to 
immunoprecipitate DHHS/C5. The reaction mix contains 500 nM recombinant 
human Gαs (Origene TP314318), non-myristoylated rat Gαi proteins (Gift of Dr. 
Carmen Dessauer and Dr. Tanya Baldwin) or recombinant human GAPDH 
(abcam ab77109), 200 nM DTT, 300 µM DDM, and 5 µM palmitoyl CoA{N-[(7-
nitro-2-1,3- benzoxadiazol-4-yl)-methyl]amino} (Avanti lipids). For samples mixed 
with hydroxylamine (HA), final concentration of 400 mM neutral HA is present in 
the reaction mix. Reactions were started by adding palm-CoA-NBD and kept 
shaking at 37°C. At the indicated time points, a portion of the reaction was taken 
out and stopped by adding lysis buffer and heating at 80°C for 15 min. Beads 
were boiled in the presence of 2% BME to check for DHHS/C5 proteins at the 
end of the reactions. All samples were run on 4-20% gradient gels, transferred, 
and imaged using a ChemiDoc XRS+ system (BIO-RAD) with a Blue Epi 
illumination and a 530/25 filter for the NBD signals. Standard Western Blotting 
was used to check for the level of total substrate proteins.  
 
Acyl-PEG-Exchange 
H9c2 cells were lysed in 1% β-D-maltoside in PBS, supplemented with a 
protease inhibitor mixture and APT inhibitor ML211 (10 µM). Acyl polyethylene 
glycol (PEG) exchange was performed as described previously with slight 
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modifications [203]. Briefly, proteins were precipitated by chloroform-methanol 
(CM) and incubated with 0.2% MMTS at 42°C for 15 min. Following four rounds 
of CM precipitation, protein pellet was dissolved in buffer containing 2% SDS, 
5mM EDTA, 100mM HEPES, PH 7.4 (refer to as 2SB). Samples were divided 
into two equal parts, and one part was incubated with 2M Hydroxylamine (HA, 
PH=7) while the other part with 2M NaCl (-HA, negative control) for 1 hr at room 
temperature with end-to-end rotation. Samples were washed with three rounds of 
CM precipitation and dissolved in 2SB. Equal volume of 2mM PEG maleimide 
(mPEG) was added to samples and incubated at room temperature for 2 hr with 
gentle mixing. Excess mPEG was removed using three rounds of CM 
precipitation and the protein pellet was dissolved in 2SB. Loading buffer 
containing 2% BME and 2mM DTT were added to the samples and heated at 
80°C for 15 min. Samples were ran on 4-20% gradient gels, followed by standard 
western blotting.   
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Chapter III: DHHC5 Mediates Beta-adrenergic Signaling Though 
Palmitoylation of G Alpha Proteins in Cardiomyocytes 
 
This chapter is partially based upon a preprint article: 
 
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) 
The palmitoyl acyltransferases DHHC5 mediates beta-adrenergic 
signaling in the heart by targeting Gα proteins and G protein-coupled 
receptor kinase 2. bioRxiv preprint. 
	
Introduction 
Beta-adrenergic receptor (β-AR) signaling is one of the central regulators 
of contractile function in the heart. Like other G protein-coupled receptors 
(GPCRs), β-ARs associate with heterotrimeric G proteins, composed of α, β, and 
γ subunits [204, 205]. Upon activation, β-ARs act as guanine nucleotide 
exchange factors and replace the GDP with GTP in the G protein α subunits 
[206]. Cardiac β-ARs associate with both Gαs and Gαi, which can stimulate or 
inhibit adenylyl cyclase, respectively [207, 208]. Adenylyl cyclase produces the 
secondary messenger cAMP, which activates multiple downstream effectors, 
including protein kinase A (PKA) [209, 210]. PKA phosphorylates many 
substrates that alter contractile functions, including ryanodine receptors, 
phospholamban, and cardiac troponin I [211-213]. Given the crucial roles of β-AR 
signaling in regulating cardiac function, it is not surprising that this pathway is 
tightly controlled.  
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Multiple members of the β-AR signaling pathway undergo protein 
palmitoylation, a posttranslational modification that adds a 16-carbon palmitic 
acid to cysteine residues via a labile thioester bond. Protein palmitoylation is 
catalyzed by a class of enzymes termed palmitoyl acyltransferases (PATs). 
There are at least 23 mammalian PATs that share a conserved Asp-His-His-Cys 
(DHHC) domain that is essential for PAT activity [68]. Most of the DHHC PATs 
are localized to the Golgi apparatus and play crucial roles in the cycling of 
palmitoylated substrates between the Golgi apparatus and the plasma 
membrane. Recently our lab showed that the plasma membrane-localized 
DHHC21 is responsible for rapid, agonist-induced palmitoylation of substrates 
downstream of the Fas death receptor in T-cells [113].  
Small G proteins such as Gα are classic palmitoylated proteins, and this 
modification is crucial for their plasma membrane targeting and subsequent 
functions [170, 171]. Studies in HeLa cells and primary hippocampal neurons 
suggested that Gα proteins can be palmitoylated by Golgi-localized DHHC3 and -
7 [214]. The enzymatic activity regulating Gα protein palmitoylation in cardiac 
tissue is incompletely understood. Recently, the β2-AR was reported to be 
palmitoylated at two cysteine residues in cardiomyocytes in a PKA-dependent 
manner resulting in internalization after 20 minutes of isoproterenol (ISO) 
stimulation [168]. In this study it was found that the Golgi-associated DHHC9, 14, 
and 18 may mediate β2-AR palmitoylation. In order for palmitoylation to regulate 
GPCR signaling with kinetics consistent with a signaling role, presumably a 
plasma membrane localized DHHC enzyme should be activated. In 
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cardiomyocytes, the plasma membrane localized DHHC5 enzyme has been 
shown to be concentrated in caveolae and regulate the dynamic palmitoylation of 
phospholemman, a regulatory subunit of the Na pump [193, 194]. Importantly, 
phospholemman palmitoylation is dependent upon PKA phosphorylation, 
indicating it is likely palmitoylated in a stimulus-dependent manner [193]. 
Whether DHHC5 regulates the dynamic palmitoylation of other substrates after β-
AR stimulation in cardiomyocytes is not known.  
Here I show that Gαs and Gαi are palmitoylated within minutes of β-AR 
activation in ventricular cardiomyocytes. The palmitoylation kinetics are 
temporally consistent with the downstream cAMP production and changes in 
contractility. Knockdown of DHHC5 significantly inhibits agonist-induced 
palmitoylation and downstream responses indicating that this enzyme is required 
for β-AR signaling in cardiomyocytes. Additionally, I show that Gαs and Gαi are 
direct substrates of DHHC5 in vitro. These results uncover a novel and essential 
palmitoylation-dependent signaling cascade downstream of β-ARs in 
cardiomyocytes.  
 
Results 
Acyl-biotin exchange reveals known and novel palmitoylation proteins in 
the cardiac β-AR signaling pathway 
Multiple methods have been developed to detect protein palmitoylation. 
The traditional method of metabolically labeling target proteins with [3H]-palmitate 
is powerful, but not ideal for unbiased identification of multiple palmitoylation 
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substrates. The efficiency of labeling is dependent on the ability of cells to 
incorporate labeled palmitate and the palmitate turnover rate of each individual 
protein [103]. In addition, exogenous addition of palmitic acid to cells may drive 
non-physiological processes including altering the acylation state of signaling 
proteins. More recently, acyl-biotin exchange (ABE, Figure 1B in Chapter I) has 
been exploited as an efficient way of detecting the endogenous palmitoyl 
proteome in various tissues and organisms [71, 109, 110]. The first step of ABE 
is blocking the free cysteine sites on proteins in cell lysates by using the 
thioreactive compound N-ethylmaleimide (NEM). Subsequently the labile 
thioester bond at the palmitoylation site is cleaved using neutral hydroxylamine 
(HA), exposing the free thiol group that can be subsequently biotinylated. After 
biotinylation, proteins are pulled down using streptavidin beads and eluted, 
followed by Western blotting to detect palmitoylated proteins. I used multiple rat 
cardiac cell types, including the myoblast cell line H9c2, neonatal rat ventricular 
myocytes (NRVM), and adult murine left ventricular tissue for detection of 
palmitoylated proteins downstream of β-AR (Figure 4A-C). I used calnexin as a 
positive control for protein palmitoylation in all experiments [215, 216]. As 
expected, I found that Gαs and Gαi are palmitoylated in both cell types and in 
cardiac tissue. Additionally, I also identified G protein-coupled receptor kinase 2 
(GRK2), a negative regulator of β-AR signaling, as a novel palmitoylation target 
in H9c2 cells. Though GRK2 has never been shown as a palmitoylated protein, 
another member of the GRK family, GRK6, has been shown to be palmitoylated 
at the carboxyl-terminal domain in COS-7 cells [178].  The PKA regulatory 
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subunit showed low levels of palmitoylation in H9c2 cells consistent with a 
previous proteomic study [217]. However, I cannot conclude that PKA regulatory 
subunit is indeed palmitoylated in H9c2 cells because the signal was only 
marginally stronger than the background signal in the -HA lane. Other methods, 
for example acyl-RAC, may be more suitable for confirming the palmitoylation 
state of PKA regulatory subunits. No palmitoylation was detected for other 
proteins downstream of β-ARs, including adenylyl cyclase 5/6 or PKA catalytic 
subunits (Figure 4A-C). Consistent with our ABE results in adult rat ventricular 
tissue (Figure 4C), a palmitoyl proteomic study in adult rat ventricular 
cardiomyocytes found that Gαs and Gαi are palmitoylated proteins [218]. 
Interestingly, Wypijewski et al. identified adenylyl cyclase 6, but not any other 
proteins listed in my study, as a potential palmitoylated protein.  
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Figure 4 Palmitoylation of cardiac proteins as determined by acyl-biotin 
exchange (ABE) 
ABE was performed on H9c2 cells (A), neonatal rat ventricular myocytes 
(NRVMs, B), and adult rat left ventricular (LV) tissue (C). Calnexin was used as a 
positive control. The absence of hydroxylamine (-HA) was used as a negative 
control for non-specific binding to the streptavidin beads. Abbreviations are as 
follows: GRK2, G protein-coupled receptor kinase 2; AC, adenylyl cyclase; PKA 
R, protein kinase A regulatory subunit; PKA C, PKA catalytic subunit. 
Overexposure of the PKA R blot is indicated as a (+). This figure is modified from 
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) The 
palmitoyl acyltransferases DHHC5 mediates beta-adrenergic signaling in the 
heart by targeting Gα proteins and G protein-coupled receptor kinase 2. bioRxiv 
preprint. Copyrights for this article remain with the authors. 
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Activation of β-ARs induces rapid protein palmitoylation in cardiomyocytes  
Previous studies indicate that stimulation of β-ARs increases the rate of 
turnover of palmitate groups on Gα [122, 171, 219]. To examine whether Gαs 
and Gαi proteins are palmitoylated upon β-AR activation in cardiomyocytes, I 
stimulated primary NRVMs with the β-AR agonist isoproterenol (ISO) and 
collected lysates from 0 to 30 minutes. I then performed ABE to quantify 
palmitoylation levels of proteins of interest. I found that both Gαs and Gαi had 
significantly increased palmitoylation levels within a minute of ISO stimulation 
(Figure 5A,B). Calnexin is a well-characterized and stably palmitoylated protein 
[215]. I found that palmitoylation levels of calnexin were marginally elevated after 
ISO stimulation. It is known that calnexin is localized to the ER [220], a separate 
membrane system from the plasma membrane where many of the β-AR 
signaling proteins are localized. Therefore, due to the modest increases in 
calnexin palmitoylation levels and localization to a separate membrane system, I 
used calnexin to normalize the changes in palmitoylation levels of Gα proteins 
(Figure 5B). By 30 min the palmitoylation levels of Gαs and Gαi were 
significantly reduced suggesting a temporally distinct activation of acyl protein 
thioesterases. Interestingly, I also found that GRK2 can be palmitoylated after 
ISO stimulation (Figure 6). The kinetics of GRK2 palmitoylation were 
characterized by increased levels at later time points compared to Gα proteins 
and were maintained throughout the 30 min time course (Figure 6B). These 
delayed kinetics may be functionally relevant to the negative regulatory role of 
GRK2 in the β-AR pathway. I next examined whether the agonist-induced 
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palmitoylation is temporally consistent to downstream events mediating 
contractile functions. To test whether the kinetics of Gα palmitoylation correspond 
to downstream cAMP production, I measured intracellular cAMP levels in NRVMs 
after ISO stimulation. We found that cAMP levels increased within a minute of 
ISO stimulation and then decreased within 30 min (Figure 5C), which was 
temporally consistent with the kinetics of Gα palmitoylation (Figure 5A,B). ISO is 
known to induce positive inotropy in NRVMs [221]. I used Fura-2 AM, a 
ratiometric calcium indicator, to monitor the intracellular calcium levels in 
spontaneously beating NRVMs. I observed an increase in calcium oscillation 
frequency (corresponding to beating frequency) within a minute of ISO 
stimulation, which like cAMP production, was temporally consistent with the 
kinetics of Gα palmitoylation (Figure 5D). These results suggest that rapid 
palmitoylation of signaling proteins after β-AR stimulation may play a role in the 
assembly of the macromolecular β-AR signaling complex and efficient 
downstream modulation of cardiomyocyte contractility. To directly address this 
possibility, I targeted the enzymatic machinery potentially responsible for rapid 
palmitoylation of signaling proteins in cardiomyocytes.  
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Figure 5 Isoproterenol induces rapid and reversible palmitoylation of Gαs 
and Gαi in cardiomyocytes 
(A) Neonatal rat ventricular myocytes (NRVMs) were treated with 10 µM 
isoproterenol (ISO) for the indicated times. ABE was used to detect 
palmitoylation levels. Calnexin, which has a relatively slow turnover of 
palmitoylation groups, was used to normalize turnover rates assessed by ABE. 
(B) Fold changes of palmitoylation levels of Gαs and Gαi normalized to calnexin 
at the indicated time points compared to 0 min (n=3). (C) NRVMs were treated 
with 10 µM ISO for indicated time points and intracellular cAMP concentration 
was measured using ELISA (n=5). (D) Representative single cell trace of the 
Fura-2 ratio in a NRVM cell treated with 10 µM ISO at the indicated time point. 
*p<0.05 (paired t test). This figure is modified from Chen, J. J., Marsden, A. N., 
Akimzhanov, A. M., & Boehning, D. (2018) The palmitoyl acyltransferases 
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DHHC5 mediates beta-adrenergic signaling in the heart by targeting Gα proteins 
and G protein-coupled receptor kinase 2. bioRxiv preprint. Copyrights for this 
article remain with the authors.  
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Figure 6 Isoproterenol induces rapid palmitoylation of GRK2 in primary 
cardiomyocytes 
(A) Neonatal rat ventricular myocytes (NRVMs) are treated with 10 µM 
isoproterenol (ISO) for the indicated times. ABE was used to detect 
palmitoylation levels of GRK2 in response to ISO stimulation. This blot was 
generated from the same ABE reaction as shown in Figure 5. (B) Quantification 
of palmitoylation levels normalized to calnexin at the indicated time points. 
*p<0.05 (paired t test, compared to time 0). This figure is modified from Chen, J. 
J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) The palmitoyl 
acyltransferases DHHC5 mediates beta-adrenergic signaling in the heart by 
targeting Gα proteins and G protein-coupled receptor kinase 2. bioRxiv preprint. 
Copyrights for this article remain with the authors. 
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The palmitoyl acyltransferase DHHC5 mediates β-AR signaling in 
cardiomyocytes  
I have previously shown that the plasma membrane-localized DHHC 
enzyme DHHC21 is responsible for rapid agonist-induced palmitoylation of 
components of the Fas receptor pathway in T cells [113]. Therefore, I 
hypothesized that the DHHC enzyme that catalyzes the ISO-induced 
palmitoylation in cardiomyocytes must similarly be localized to the plasma 
membrane. In addition to DHHC21, DHHC5 is one of the few DHHC enzymes 
that has been shown to be at least partially plasma membrane localized [70]. At 
the transcript level, DHHC5 is abundantly expressed in rat cardiomyocytes [194]. 
I analyzed the localization of endogenous DHHC5 in NRVMs. 
Immunofluorescence staining showed that DHHC5 has Golgi/ER and plasma 
membrane localization (Figure 7A). To determine whether DHHC5 is responsible 
for ISO-induced palmitoylation in NRVMs, I used siRNA to knockdown DHHC5 
(Figure 7B,C). I also confirmed that siRNA knockdown of DHHC5 did not affect 
the total proteins level of Calnexin, Gαs, or Gαi (Figure 7D,E). I then performed 
ABE and found that agonist-induced palmitoylation of Gαs and Gαi is 
undetectable in DHHC5 knockdown cells (Figure 8A-B). Next I determined 
whether DHHC5 activity is required for signaling downstream of ISO stimulation 
in NRVMs. I found that DHHC5 knockdown cells have diminished levels of cAMP 
production following ISO stimulation (Figure 8C). Additionally, I found that 
DHHC5 knockdown cells no longer have an increased calcium oscillation 
frequency in response to ISO stimulation (Figure 8D). These data indicate that 
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DHHC5 is essential for signaling through the β-AR pathway in cardiomyocytes, 
and this is likely mediated at least in part by regulating the palmitoylation state of 
Gα proteins. To address whether my observation in cardiomyocytes are due to 
Gαs and Gαi being direct substrates of DHHC5, I utilized an in vitro assay to test 
DHHC5 enzymatic activity in the presence of recombinant protein substrates.  
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Figure 7 Localization of DHHC5 in primary cardiomyocytes 
(A) Immunofluorescence staining of neonatal rat ventricular myocytes (NRVM) 
with anti-DHHC5. Golgi apparatus localization is indicated by arrows, and plasma 
membrane localization is indicated by arrowheads. 71% of all NRVM cells (n=24 
from 5 samples) showed plasma membrane localization as determined by 
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blinded scoring. (B-E) Western blot analysis of NRVMs transfected with control 
(Cont) and a mixture of two siRNAs targeting DHHC5 (KD). GAPDH is used as a 
loading control. Same blot was stripped and re-probed with Calnexin, Gαs, and 
Gαi to make sure there was no off-target effect on the proteins of interest. 20-40 
µg of total proteins were loaded for the indicated lanes. The same siRNAs are 
used to generate the data in Figure 8 of this chapter.  
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Figure 8 DHHC5 is required for signaling downstream of β-adrenergic 
receptor stimulation in cardiomyocytes 
 (A) Palmitoylation of Gαs, Gαi, and calnexin in control and DHHC5 knockdown 
(KD) NRVMs treated with 10 µM isoproterenol (ISO) for indicated time points. (B) 
Fold changes of palmitoylation levels of Gαs and Gαi normalized to calnexin at 
the indicated time points compared to 0 min (n=3). (C) Quantification of cellular 
cAMP levels before and after ISO (5 min) in control (black) and DHHC5 
knockdown (red) NRVMs (n=3). (D) Quantification of beating frequency 
monitored by Fura-2 before (baseline) and after ISO (+ISO) in control (black) and 
knockdown (red) cells (n=5). *p<0.05; n.s. = not significant (paired t test). This 
figure is modified from Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & 
Boehning, D. (2018) The palmitoyl acyltransferases DHHC5 mediates beta-
adrenergic signaling in the heart by targeting Gα proteins and G protein-coupled 
receptor kinase 2. bioRxiv preprint. Copyrights for this article remain with the 
authors. 
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DHHC5 palmitoylates Gαs and Gαi in vitro 
In collaboration with Dr. Marsden, I adopted a previously described in vitro 
palmitoylation assay using a fluorescently labeled palmitoyl-CoA analog, 
palmitoyl CoA{N-[(7-nitro-2-1,3- benzoxadiazol-4-yl)-methyl]amino} (NBD). It was 
used to demonstrate that purified human DHHC20 and zebrafish DHHC15 can 
robustly palmitoylate Legionella ubiquitin ligase GobX and human SNAP25B, 
respectively [186]. We overexpressed FLAG-tagged human DHHC5 or the 
catalytically inactive form DHHS5 in HEK293 cells, immunoprecipitated 
DHHC/S5, and performed an on-bead enzymatic assay. To establish that the 
NBD fluorescent signal is attached to the substrates via thioester bonds, we 
added hydroxylamine to the reaction mix as a negative control (Figure 9). For 
both no enzyme and catalytically inactive DHHS5 controls, we observed some 
level of autoacylation of Gα proteins, which has been reported in previous studies 
using [3H]Palmitoyl-CoA in vitro (Figure 10A,B; [222]). In the presence of 
DHHC5, the rate of Gαs and Gαi palmitoylation was accelerated.  In contrast, the 
known palmitoylated protein GAPDH [223] showed no increased palmitoylation in 
the presence of DHHC5 indicating substrate specificity (Figure 10C). 
Additionally, an N-terminal mCherry-fused variant of DHHC5 performed similarly 
to the FLAG-tagged variant validating that N-terminal tags do not appreciably 
impact enzymatic activity or substrate recognition of this enzyme (Figure 11). 
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Figure 9 Procedures of in vitro assay to identify direct substrates of DHHC5 
First, flag-tagged DHHC5 or catalytically inactive DHHS5 were 
immunoprecipitated (IP). The reaction was carried out on-bead with recombinant 
substrate proteins and the Palm-CoA{N-[(7-nitro-2-1,3- benzoxadiazol-4-yl)-
methyl]amino} (NBD). Hydroxylamine (HA, red) was added as a negative control 
to ensure the NBD signal detected is link to substrates via thioester bonds.  
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Figure 10 Gαs and Gαi are direct substrates of DHHC5.  
Palmitoylation of recombinant Gαs (A), Gαi (B), and GAPDH (C) in vitro with 
mock IP (-), catalytically inactive form of DHHC5 (DHHS5), and DHHC5. As a 
negative control, hydroxylamine (HA) is added to cleave palmitoylation. DHHC 
total input as determined by Western blotting is shown below the palmitoylation 
panels. 
 
  
 56 
 
 
 
Figure 11 mCherry-DHHC5 is catalytically active 
(A-C) In vitro DHHC assay as in Figure 4 of the main text using mCherry-DHHC5 
instead of FLAG-DHHC5. Palmitoylation of recombinant Gαs (A), Gαi (B), and 
GAPDH (C) in vitro with mock IP (-), catalytically inactive form mCherry-DHHS5, 
and mCherry-DHHC5. As a negative control, hydroxylamine (HA) is added to 
cleave all thioester bonds. 
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Discussion 
Rapid, agonist-induce palmitoylation in signaling transduction 
Palmitoylation is the only reversible lipid modification, and a growing list of 
signaling proteins are known to undergo cycles of palmitoylation and 
depalmitoylation [224, 225]. Recently, our group showed that the tyrosine kinase 
Lck can be palmitoylated within a minute of Fas ligand stimulation in T cells, 
suggesting that palmitoylation plays key role in rapid signal transduction 
analogous to other post-translational modifications such as phosphorylation 
[113]. Multiple members of the Gα protein family, including Gαs and Gαi, have 
been shown to be palmitoylated in the N-terminus [170, 219]. In cell lines, 
overexpression of Gαs and Gαi palmitoylation mutants showed defects in 
membrane association [171, 226]. Stimulation of β-ARs in kidney fibroblast-like 
COS cells and S49 lymphoma cells did not lead to detectable changes in Gα 
protein palmitoylation levels using high performance liquid chromatography 
(HPLC) [123], though an earlier study found that [3H]palmitate had increased 
turnover after ISO stimulation [122]. One possible explanation is that 
[3H]palmitate loading only labels a small fraction of the total Gα pool, which 
cannot be detected using HPLC. Recent advances in palmitoylation detection 
methods allow us to better study dynamic palmitoylation of endogenous Gα 
proteins with endogenous lipids and their functional outcomes in specific cell 
types. My data demonstrate extremely rapid palmitoylation kinetics of Gα 
proteins following activation of the β-ARs and its temporal correlation with 
downstream events in cardiomyocytes. The requirement of palmitoylation for β-
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AR signaling were functionally demonstrated by transient knockdown of DHHC5, 
which reduced or eliminated the majority of downstream effects of ISO 
stimulation in cardiomyocytes. 
 
DHHC5 is a novel regulator of cardiac functions 
Few studies have examined the cellular function of DHHC5 and its link to 
human diseases. One of the known substrates of DHHC5 is the neuronal 
scaffolding protein PSD-95, which is enriched at the postsynaptic sites in 
neurons [227]. Mice homozygous for a hypomorphic allele of Zdhhc5 gene 
showed defects in learning and memory [227]. Curiously, PSD-95 palmitoylation 
levels are not decreased in the hypomorphic mice, likely because PSD-95 can 
also be palmitoylated by other DHHC enzymes in neurons [228]. Some of the 
homozygous DHHC5 hypomorphic mice show lethality, suggesting its role in 
early development [227]. Cardiomyocytes isolated from these mice showed 
reduced massive endocytosis, a process that happens during re-oxygenation of 
anoxic hearts [197]. Phospholemman and the cardiac Na/Ca exchanger were 
identified as potential substrates of DHHC5 in regulating massive endocytosis 
[197]. Several other studies on cardiac functions of DHHC5 also focus on its 
substrate phospholemman in regulating sodium pumps in adult ventricular 
myocytes [193, 194]. My data identify β-AR signaling, a pathway that is closely 
associated with heart failure and is a major therapeutic target in cardiovascular 
diseases, as a key target for the enzymatic action of DHHC5.  
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Efficient detection of DHHC enzyme substrates in vitro 
 Several methods have been used to study palmitoylation of a specific 
substrate by a DHHC enzyme of interest. For example, in the first study that 
identified yeast transmembrane protein Akr1p to be a PAT, an in vitro assay was 
used to showed that Akr1p can palmitoylate the type I casein kinase Yck2p [184]. 
This method utilized [3H]palmitoyl-CoA, purified Yck2p and Akr1p, in the 
presence of ATP, MES, and bovine liver lipids [184]. Recently, a radiolabeling-
free method was used to show that purified human DHHC20 and zebrafish 
DHHC15 palmitoylate ubiquitin ligase GobX and SNAP25B, respectively [187]. A 
dye conjugated to palmitoyl-CoA was used instead of [3H]palmitoyl-CoA. My 
study modified this method further by performing an on-bead assay after 
immunoprecipitating DHHC5, thus eliminating the necessity of having purified 
DHHC enzymes. Additionally, my method showed substrate specificity because 
DHHC5 did not palmitoylate GAPDH, a known palmitoylated protein.   
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Chapter IV: The H9c2 cell line as an alternative to study protein 
palmitoylation in β-AR pathways 
 
Introduction 
 The H9c2 cell line is derived from BDIX rat ventricular heart tissue after 
selective serial passages [229]. The original study described that H9c2 cells are 
multinucleated, non-beating, spindle-shaped cells that show morphological, 
biochemical, and electrophysiological features of muscle cells. Specifically, 
electron microscopy revealed that the T-tubule structures of H9c2 cells were 
more similar to those of skeletal muscle cells but not cardiac muscle cells [229]. 
One later study found that the majority of H9c2 cells are mononucleated, and did 
not have gap junctions, caveolae, or T-tubules [230]. Further examination of the 
electrophysiological properties revealed that after couple of weeks in culture, 
H9c2 cells show inward voltage-dependent calcium currents similar to that of 
cardiac muscle cells but not skeletal muscle cells. They also showed that H9c2 
cells responded to isoproterenol stimulation and increased intracellular cAMP 
[230]. Therefore, many studies focusing on cardiac signaling pathways have 
since used H9c2 cells as a model. For example, one study found that H9c2 cells, 
similar to NRVMs, display hypertrophic responses to both angiotensin II and 
endothelin-1 [231].  
 Interestingly, H9c2 cells have 30% β1-AR and 70% β2-AR, a ratio that is 
the opposite of that in rat heart tissue, but similar to that in human heart [232]. In 
response to prolonged β-AR stimulation, β2-AR was down regulated both at the 
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protein level and at the mRNA level [232], similar to the observation in NRVMs 
that β2-ARs were reduced at the cell surface [233]. Despite the lack of caveolae 
in H9c2 cells [230], one recent study showed that β1-AR and β2-AR are confined 
to certain regions of the plasma membrane, and their interactions with anchoring 
proteins are crucial for these localization patterns [234]. Given the similarities of 
H9c2 cells with other cardiac cell models, I am interested in using it as an 
alternative model to study DHHC5-mediated palmitoylation of Gα proteins. One 
study showed that distinct classes of proteins can be palmitoylated in H9c2 cells 
using [3H]palmitate labeling [235]. However, the identities of those proteins 
remain uncharacterized. Additionally, the localizations and functions of DHHC 
enzymes in H9c2 cells remain unknown.  
 
Results 
Activation of β-ARs does not induce rapid protein palmitoylation in H9c2 
cells 
Previous studies have shown that H9c2 cells are prone to further 
differentiation when maintained in culture [236]. To verify that my culture of the 
H9c2 cells still possess cardiac muscle properties, I stimulated the H9c2 cells 
with endothelin-1 (ET-1), a peptide released by endothelial cells that stimulates 
the ETA and the ETB receptors [237]. Previous study showed that H9c2 cells 
expressed high level of ETA receptors and showed calcium release from the SR 
storage in response to ET-1 stimulation, a process mediated by the RyRs [238]. I 
used Fura-2 AM to monitor intracellular calcium level in live H9c2 cells. After 
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stimulation with ET-1, in over 70% of the cells imaged we observed a calcium 
transient (Figure 12A). Next, I want to study if there is stimulus-dependent rapid 
palmitoylation of Gα proteins after ISO stimulation in H9c2 cells, like I observed 
in NRVMs. I stimulated the cells with 10 µM ISO and performed ABE at the 
indicated time points. I observed no change in palmitoylation levels of either Gαs 
or Gαi proteins (Figure 12B). Downstream of the β-AR signaling pathway, I 
found no significant change in cAMP levels after ISO stimulation (Figure 12C,D). 
Additionally, there is no increase in intracellular calcium levels after ISO 
stimulation (Figure 12E). These data suggested that despite the presence of the 
β-AR signaling pathway, there is no rapid palmitoylation or inotropic responses to 
ISO stimulation in H9c2 cells like those observed in NRVMs.  
 Next, I investigated if DHHC5 has similar localization patterns in H9c2 
cells. Immunofluorescence staining showed that unlike in NRVMs, DHHC5 has 
only Golgi/ER but no plasma membrane localization in H9c2 cells (Figure 13A). 
These data combined suggested that H9c2 is not an ideal model for studying 
rapid palmitoylation or more generally, contractile responses following β-AR 
stimulation.   
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Figure 12 Isoproterenol induces no increased palmitoylation of Gα proteins 
in H9c2 cells 
(A) Representative single cell trace of the Fura-2 ratio in a H9c2 cell treated with 
1 µM endothelin-1 (ET-1) at the indicated time point. (B) H9c2 cells were treated 
with 10 µM isoproterenol (ISO) for the indicated times. ABE was used to detect 
palmitoylation levels. (C) Representative trace of H9c2 cells treated with 10 µM 
ISO for indicated time points and intracellular cAMP concentration was measured 
using ELISA. (D) Quantification of cellular cAMP levels before and after ISO 
(2min) in H9c2 cells (n=3). (E) Representative single cell trace of the Fura-2 ratio 
in a H9c2 cell treated with 10 µM ISO at the indicated time point.   
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Figure 13 Localization of DHHC5 in H9c2 cells and NRVMs 
Immunofluorescence staining of H9c2 cells (A) and neonatal rat ventricular 
myocytes (B) with anti-DHHC5. Golgi apparatus localization is indicated by 
arrows, and plasma membrane localization is indicated by arrowheads. (C) 
Quantification of the percentage of cells with plasma membrane localize DHHC5 
(n=5, * p<0.05, unpaired T test).  
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Identifying potential cardiac protein palmitoylation sites in H9c2 cells 
My ABE data showed that in h9C2 cells, GRK2 was palmitoylated with no 
ISO stimulation (Figure 4A). Since there was no previous report on GRK2 being 
a palmitoylated substrate, we used Acyl-PEG exchange (APE, Figure 14A) 
assay [203] to find the number of potential palmitoylation sites on GRK2. APE 
shares similar steps with ABE—free cysteine sites were first blocked using NEM, 
followed by cleaving the palmitoylation site. Then a 5 kDa PEG was added to the 
palmitoylation site and analyzed after Western blotting. Calnexin has two 
palmitoylation sites [215] and was used as a positive control. I found that Gαs 
and Gαi showed one single shift in molecular weight, consistent with previous 
findings that Gαs and Gαi are palmitoylated at one single cysteine at the N-
terminus (Figure 14B; [170]). I found that there was a single shift of GRK2 
protein indicating that there is only one palmitoylation site (Figure 14B). 
However, further mutagenesis study is still needed to identify the palmitoylation 
site.  
 
Discussion 
 In Chapter III we showed that in NRVMs, ISO stimulation leads to rapid 
palmitoylation of Gα proteins by DHHC5. Despite previous studies reporting that 
the β-ARs and their downstream signaling proteins are present in H9c2 cells, I do 
not find similar rapid palmitoylation or downstream inotropic effects in my study. 
Since I proposed that rapid palmitoylation of Gα proteins recruits them  
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Figure 14 Identifying number of palmitoylation sites using Acyl-PEG 
exchange assay  
(A) Schematics of acyl-PEG exchange (APE) assay. The free cysteine sites are 
blocked, followed by cleaving the thioester bond at the palmitoylation site, and 
addition of a mass-tag of certain size. (B) APE assay using 5kD PEG on H9c2 
cells. Calnexin was used as positive control. White arrowheads indicate non-
palmitoylated proteins. Black arrowheads indicate palmitoylated proteins. Grey 
arrowheads indicate non-specific background signals that are equal in -HA and 
+HA lanes (NS).  
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into membrane subdomain caveolae for efficient signaling transduction, it is 
possible that the lack of caveolae in H9c2 cells [230] lead to the absence of such  
mechanisms. Additionally, I also found that endogenous DHHC5 is almost 
exclusively localized to the Golgi/ER membrane, but not on the plasma 
membrane in H9c2 cells. Though I cannot exclude the possibility that other 
plasma membrane localized DHHC enzymes (DHHC20 or 21) may be able to 
mediate rapid palmitoylation near the plasma membrane, it is clear that the 
mechanisms of ISO-induced rapid signaling events are absent in H9c2 cells, and 
therefore it is not a suitable model for studying stimulus-dependent palmitoylation 
downstream of β-AR signaling.  
 Since GRK2 is palmitoylated without stimulation in H9c2 cells, I was able 
to identify a single palmitoylation site on the protein. Previous studies have 
shown that two other GRK family proteins, GRK4 and 6, are palmitoylated [178, 
179]. GRK6 is palmitoylated at a cluster of cysteines near the C-terminal end at 
position 561, 562, and 565 [178]. Based on an analogous alignment, GRK4 is 
predicted to be palmitoylated at position 561 and 578 [179]. However, these sites 
are not conserved in GRK2 and therefore further studies are required for 
identifying the palmitoylation site(s).  
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Chapter V DHHC5 is regulated by palmitoylation and 
phosphorylation of the C-terminal tail 
 
Introduction 
DHHC5 has a ~500 amino acid (more than 70% total length of the protein) 
C-terminal tail that is proposed to contain regulatory components that are crucial 
for substrate recognition, localization, activation, and other potential functions 
[194, 198, 199]. Truncation mutations of DHHC5 showed that the region between 
amino acids 218 and 334 is necessary for recognizing substrates including 
phospholemman and flotillin 2 [194]. In neurons, the tyrosine kinase Fyn 
phosphorylates DHHC5 at Y533 and stabilizes it at the synapse by forming a 
DHHC5/Fyn/PSD-95 protein complex [198]. In adult mouse forebrain extracts, 
DHHC5 was found to be palmitoylated at three potential cysteines in the C-
terminus tail, some of which are conserved in other DHHC enzymes [199]. One 
recent study showed that DHHC6 is palmitoylated in the C-terminal tail by 
DHHC16, revealing a novel palmitoylation cascade to fine-tune DHHC activities 
[190].  However, the functional consequences of DHHC5 C-terminal tail 
palmitoylation remain largely unknown.  
Palmitoylation of various transmembrane proteins has been shown to 
affect their localizations in membrane subdomains or their interaction with other 
transmembrane proteins [64, 239-241]. To elucidate the potential functional 
outcomes of DHHC5 palmitoylation specifically at the plasma membrane, we 
need to exclude the population of DHHC5 proteins localized at the Golgi 
apparatus membrane. Therefore, we utilized total internal reflection fluorescence 
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(TIRF) microscopy to monitor fluorescently tagged DHHC5 proteins in live cells. 
This technique is based on the theory of total internal reflection at the interface 
between the coverslip (glass) and the sample (cells in media) when the light 
source hits at a specific angle (critical angle) [242]. The reflection results in an 
electromagnetic field generating the evanescent wave that excites only the 
fluorophores close to the coverslip [243]. The thickness of the evanescent field is 
dependent on the wavelength of the laser, illumination angle, and other factors 
[242]. Some of the advantages of TIRF microscopy compared to traditional 
epifluorescence microscopy include less photobleaching, little out-of-focus 
fluorescence signals, and higher signal-to-noise ratio. TIRF microscopy, 
sometimes combined with other techniques such as fluorescence resonance 
energy transfer, has been used to monitor membrane protein properties including 
their lateral mobility, clustering, and endocytosis in live cells [244-247]. In live 
neonatal and adult ventricular myocytes, TIRF microscopy has been used to 
monitor dynamic SR formation and rearrangements, ryanodine receptor 
localization and clustering, and L-type calcium channel localization [248, 249]. 
Therefore, we believe that TIRF microscopy is useful in assessing the dynamic 
localization of DHHC5 in NRVMs.  
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Results 
The C-terminal tail of DHHC5 is palmitoylated upon stimulation of β-ARs to 
modulate downstream signaling in cardiomyocytes 
DHHC5 contains a C-terminal tail that can be a target for post-translational 
modifications to modulate enzyme structure/function (Figure 15) [250]. Three 
potential palmitoylation sites in the C-terminal tail of DHHC5 have previously 
been identified in mouse forebrain extracts (highlighted in Figure 15) [199]. In 
order to determine if these sites are palmitoylated in NRVMs, I created single 
mutants that changes Cys 236 or 245 to Ser, double mutant that changes both 
Cys 236 and 245 to Ser, and removed all three potential palmitoylation sites by 
deleting amino acids 236-245 (refer to as Δ236-245). DHHC enzymes are 
autocatalytically modified at the active site with palmitate [185], and thus I 
performed all ABE experiments using the catalytically dead mCherry-DHHS 
constructs expressed in NRVM to only examine palmitoylation in the C-terminal 
tail. I observed that the single mutants, the double mutant, and the deletion 
mutant all showed no palmitoylation in the C-terminal tail (Figure 16A). These 
data suggest that all three sites are palmitoylated and the absence of any one 
site interferes with the palmitoylation at other sites. Next, Ie examined whether 
the palmitoylation of the three Cys in the C-terminal tail changes after ISO 
stimulation. I performed an ABE time course on the catalytically dead mCherry-
DHHS5 and mCherry-DHHSΔ236-245. I found that DHHS5 is palmitoylated 
within one minute upon ISO stimulation, while this is lost in the DHHSΔ236-245 
mutant (Figure 16B). This indicates that the C-terminal tail of DHHC5 is very 
 71 
rapidly palmitoylated in this cluster of Cys residues upon β-AR stimulation. To 
address the functional outcomes of DHHC5 tail palmitoylation upon stimulation, I 
knocked down DHHC5 in NRVMs and rescued downstream cAMP production 
with both wild-type mCherry-DHHC5 and mCherry-DHHC5Δ236-245 (Figure 
17A). I found that wild-type mCherry-DHHC5 restored cAMP production following 
ISO stimulation, while mCherry-DHHC5Δ236-245 was incapable of rescuing 
cAMP production (Figure 17B). Therefore, I conclude that palmitoylation of the 
DHHC5 C-terminal tail is crucial for β-AR signaling. In collaboration with Dr. 
Marsden and Dr. Scott, I next tested the hypothesis that DHHC5 palmitoylation in 
the C-terminal tail leads to sequestration in membrane microdomains where it 
can assemble with other components of the β-AR signaling pathway to facilitate 
downstream signaling [149, 251, 252]. 
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Figure 15 Schematic of DHHC5 protein and the potential posttranslational 
modifications in the C-terminal tail 
Schematic of DHHC5 created by Protter [250]. The catalytic site DHHC is 
highlighted in the green box. Three potential palmitoylation sites (236, 237, and 
245) within the tail are enlarged and highlighted. Serine 376 and Serine 584, at 
which truncation mutants have been made, are heighted (blue arrows).  
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Figure 16 DHHC5 is palmitoylated at cysteines position 236, 237, and 245 
after ISO stimulation 
(A) ABE was used to detect palmitoylation of mCherry-DHHS5 wild-type (WT), 
Cys 236 to Ser (C236S), Cys 245 to Ser (C245S) single mutants, Cys 236 & 245 
to Ser double mutant (C236S C245S), and Cys 236 to Cys 245 deletion mutant 
(Δ236-245) in NRVMs. (B) Palmitoylation of mCherry-DHHS5 and mCherry-
DHHS5Δ236-245 in NRVMs treated with 10 µM isoproterenol (ISO) for indicated 
time points. Calnexin is used as positive control. 
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Figure 17 Palmitoylation of the C-terminal tail of DHHC5 regulates signaling 
in NRVM 
(A) Western blot analysis of NRVMs transfected with control siRNA (Cont), 
siRNA targeting DHHC5 (KD), siRNA targeting DHHC5 and wild-type mCherry-
DHHC5 (KD+WT), siRNA targeting DHHC5 and mCherry-DHHC5Δ236-245 
(KD+Δ236-245). Endogenous DHHC5 and overexpressed mCherry-DHHC5 are 
indicated by black and red arrowheads (left), respectively. GAPDH (black 
arrowhead, right) is used as a loading control. (B) Quantification of cellular cAMP 
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levels in control (black), knockdown (red), and knockdown and rescue with either 
wild-type mCherry-DHHC5 (green) or mCherry-DHHC5Δ236-245 (blue) in 
NRVMs. *p<0.05; N.S. = not significant (paired t test, n=3). 
  
 76 
Palmitoylation of the C-terminal tail of DHHC5 regulates stimulation-
dependent plasma membrane motility 
To determine the effect of palmitoylation on DHHC5 membrane motility, 
Dr. Marsden, Dr. Scott and I utilized total internal reflection fluorescence (TIRF) 
microscopy [243]. We imaged live, beating NRVMs transfected with mCherry-
DHHC5 and mCherry-DHHC5Δ236-245. Both proteins were expressed in the 
TIRF plane as laterally mobile puncta of various fluorescent intensities 
presumably representing either single molecules or oligomers (Figure 18A-B) 
[72, 253]. First, we confirmed that mCherry-DHHC5Δ236-245 can localize to the 
plasma membrane appropriately like the wild-type proteins, with similar number 
of observed particles in the TIRF plane (Figure 18C). We then examined the 
lifetime of mCherry-DHHC5 particles in the TIRF plane to examine whether there 
is stimulus-dependent removal or insertion of DHHC5 into the plasma 
membrane. To accomplish this we used kernel density estimate analysis [254, 
255] to calculate the lifetime of particles before and after 10 min of ISO 
stimulation (Figure 18D-E). When comparing the particle distributions before and 
after ISO stimulation, we observed a shift to longer lived particles after β-ARs 
were activated (Figure 18D). In contrast, the mCherry-DHHC5Δ236-245 showed 
the opposite result (Figure 18E). Thus, ISO stimulation led to the stabilization of 
DHHC5 particles at the membrane, an effect that is lost in the palmitoylation 
deficient DHHC5 mutant. 
TIRF imaging has been widely used to examine lateral mobility of proteins 
in response to receptor stimulation in multiple systems [256-258]. We next 
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examined the lateral mobility of DHHC5 in the plasma membrane before and 
after ISO stimulation. To quantify this, we calculated the mean squared 
displacement (MSD) of all particles present before and after 10 min of ISO 
stimulation. MSD calculates the summation of particle movement over time [259]. 
Stalling particles will show a straight horizontal line as a function of time, while 
those moving quickly will show a steep slope.  We found that the MSD of 
mCherry-DHHC5 particles remains essentially unchanged before and after ISO 
stimulation indicating no change in lateral mobility (Figure 18F). In contrast, the 
mCherry-DHHC5Δ236-245 particles have an increase in the MSD after ISO 
stimulation indicative of increased mobility (Figure 18G). In total, these data 
indicate that DHHC5 is palmitoylated in the C-terminal tail after ISO stimulation 
(Figure 16B), leading to stabilization in the plasma membrane (Figure 18D,F). 
The DHHC5Δ236-245 mutant cannot be palmitoylated (Figure 16B), leading to 
decreased lifetime at the membrane and increased motility (Figure 18E,G), 
presumably reflecting increased ISO-stimulated removal from the TIRF plane. 
Thus, palmitoylation of the DHHC5 C-terminal tail is critical for maintaining the 
enzyme at the membrane after β-AR stimulation with potentially significant 
consequences for palmitoylation-dependent signaling cascades. 
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Figure 18 Palmitoylation of the C-terminal tail of DHHC5 regulates 
stimulation-dependent plasma membrane motility 
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TIRF images of live NRVM transfected with mCherry-DHHC5 (A) and mCherry-
DHHC5Δ236-245 (B). (C) Average number of particles in the TIRF planes over 
the 10 minute experiments for mCherry-DHHS5 (blue) and mCherry-
DHHC5Δ236-245 (orange). 95% confidence intervals are shown as 
corresponding shaded areas and there is no difference because of the overlaps. 
(D-E) Histogram with kernel density estimation (KDE) of the life-time of particles 
at 0 (blue) and 10 min (orange) after isoproterenol (ISO) stimulation. (F-G) Mean-
squared displacement (MSD) shown in 30 second windows of particles that exist 
continuously from 0 to 10 min of ISO stimulation. Each line represents one 
particle. n=377 for mCherry-DHHC5 (D and F) and n=221 for mCherry-
DHHC5Δ236-245 (E and G).  
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The C-terminal tail of DHHC5 is phosphorylated in response to stimulation 
In addition to palmitoylation in the C-terminal tail, a previous study that 
performed in vivo phosphoproteomics analysis in murine hearts also identified 
multiple potential phosphorylation sites in DHHC5, including Ser at position 380, 
425, 432, 554, and 636 [260].  Additionally, they observed that the 
phosphorylation of Ser 636 is up regulated in response to β1AR stimulation, 
potentially targeted by PKA [260]. Therefore, Dr. Marsden and I investigated 
whether the C-terminal tail of DHHC5 is phosphorylated in NRVM after β-AR 
stimulation. We used ISO and forskolin, a direct activator of ACs [261], and found 
that endogenous DHHC5 proteins showed increased phosphorylation levels after 
both stimulations (Figure 19A). The C-terminal tail of DHHC5 has 79 serine 
residues. To narrow down the potential phosphorylation sites, we created 
truncation mutants of mCherry-DHHC5 that change Ser 584 and 376 (highlighted 
in Figure 15) to stop codons. Overexpression of the mutant proteins in NRVM 
after ISO stimulation showed that DHHC5 is phosphorylated between position 
376 and 583 (Figure 19B). There are 38 serines in between position 376 and 
583. Therefore, further studies are still required to pinpoint the positions of 
phosphorylated Ser site(s) on DHHC5, identify the kinase(s) and phosphatase(s) 
that regulate its phosphorylation levels, and how phosphorylation affects DHHC5 
activity in NRVM. 
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Figure 19 DHHC5 is phosphorylated in response to β-AR stimulations 
(A) Western blot analysis using phospho-serine specific antibodies (pSer) on 
immuno-precipitated endogenous DHHC5 proteins from NRVMs stimulated with 
10 µM forskolin or isoproterenol (Iso) for 5 minutes. (B) NRVMs are not 
transfected (-) Control, or transfected with wild-type mCherry-DHHC5 (DHHC5), 
truncated mCherry-DHHC5 where Ser 584 (584 Stop) or Ser 376 (376 Stop) is 
mutated to a stop codon. After Iso stimulation, mCherry-DHHC5 proteins are 
immunoprecipitated and analyzed using pSer antibodies. mCherry antibodies 
were used to detect total protein levels.   
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Discussion 
Lipid subdomains and beta-adrenergic signal transduction in the heart 
Lipid subdomains have been proposed to create signaling centers to 
facilitate both signal propagation and inhibition. One of the lipid subdomains 
present within many cell types is caveolae. Within cardiomyocytes, caveolae are 
composed of caveolin-3, cholesterol, and sphingolipids. Caveolin proteins have 
been proposed to create a scaffold, allowing signaling complexes to form at the 
membrane. Multiple components of β-AR signaling have been identified in 
caveolae, such as β2-AR, Gαs, AC5/6 and Gαi [149, 251, 252], indicating that 
caveolae are central organizers of this pathway. DHHC5 itself has been shown to 
be present in the caveolae, allowing for direct palmitoylation of phospholemman 
[194]. Proteomic studies identified that palmitoylated proteins are predominantly 
found in caveolae, suggesting that this is a better predictor of caveolae 
localization than caveolin binding motifs [32]. My findings that DHHC5 is 
palmitoylated in the C-terminal tail upon stimulation and this modification is 
crucial for downstream cAMP production in cardiomyocytes implies that DHHC5 
as well as its targets are likely enriched in caveolae to allow efficient signaling 
transduction.  
In cardiomyocytes, not much is known about DHHC enzyme regulation. 
My findings highlight the central role of the C-terminal tail in modulating DHHC5 
function in cardiomyocytes. In particular, we found that palmitoylation of the tail 
had dramatic effects on plasma membrane retention after activation of the β-AR 
pathway.  
 83 
 
DHHC5 phosphorylation and beta-adrenergic signaling 
The tail region is highly variable in the DHHC family of enzymes, indicating 
this region may be a central mediator of isoform-specific function and substrate 
recognition. We identified that DHHC5 is phosphorylated at one or multiple 
serine(s) between amino acids 376 and 583 in response to β-AR stimulation. Our 
group found a positive feedback mechanism in T cells where Lck is palmitoylated 
rapidly by plasma membrane localized DHHC21, which is activated by 
downstream Ca2+ release [113]. Therefore, we hypothesize that a similar 
mechanism may be present in cardiomyocytes where the phosphorylation of 
DHHC5 is mediated by PKA, a kinase that is activated downstream of β-AR. My 
results combined with a previous proteomic study [260] suggest that serines at 
positions 380, 425, 432, and 554 are all likely phosphorylation sites. Future 
studies will need to address how phosphorylation affects DHHC5 functions and 
downstream signaling.  
  
 84 
Chapter VI Conclusion and Future Directions 
 
 β-AR signaling pathways are among the most well-studied pathways in the 
heart under both physiological and pathological conditions. In this study, I 
focused on the rapid changes mediating contractile functions after stimulation of 
the β-ARs in primary cardiomyocytes. Though Gα proteins have been previously 
identified as palmitoylated proteins with relatively fast turnover, relatively little is 
known about how the rapid changes of endogenous palmitoylation levels impacts 
cardiomyocytes physiology. In this study, I examined the functions of cardiac 
DHHC5 and its direct targets Gα proteins in mediating ISO-induced changes in 
contractility. 
 
Distinctive palmitoylation profiles of β-AR signaling pathway in various 
cardiac cells 
 The rat myoblast cell line H9c2 has been used in various studies that 
examine the β-AR signaling pathways [231, 232]. Since β-ARs and downstream 
proteins are expressed in H9c2 cells and there are reports of ISO-induced cAMP 
production [230], I decided to use H9c2 cells as one of the models in my study 
because they are easier to maintain and perform molecular studies when 
compared to primary cardiomyocytes. The majority of my study is carried out in 
neonatal rat ventricular myocytes (NRVMs) because there are well established 
methods to monitor multiple downstream effects of β-AR signaling, including 
cAMP production and rate of spontaneous beating [200]. Despite the wide use of 
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NRVM as a model for studying β-AR signaling, it is often criticized for not being 
as fitting a model for adult cardiomyocytes, especially in studies related to 
pathological conditions such as heart failure. Therefore, at the beginning of my 
study (Chapter III), I decided to identify the palmitoylated proteins in the β-AR 
signaling pathways in all three cell types. I found that NRVM and adult rat 
ventricular tissue shared similar palmitoylation protein targets, while H9c2 cells 
showed GRK2 as an additional palmitoylated protein. Later I found that GRK2 
can also be palmitoylated in NRVM, but only after ISO stimulation. My data 
indicate that the kinetics of proteins palmitoylation vary between different cardiac 
tissues, but the overall palmitoylated protein targets are similar among all three 
cell types examined. It should be noted that the adult rat ventricular tissue 
contains many cell types, of which myocytes comprise a minority. To fully 
understand the roles of palmitoylation on signaling proteins downstream of β-ARs 
in adult cardiomyocytes, future studies should be carried out in primary adult rat 
ventricular myocytes (ARVMs). 
 The detected palmitoylated proteins in my study differ in some respects 
from previous reports. For example, the PKA regulatory subunit is reported to be 
palmitoylated in a proteomic study [217], but in my study I cannot conclusively 
determine if it is palmitoylated given the relatively low level of signal compared to 
the negative control. Additionally, I was also not able to detect AC6 
palmitoylation, which was reported in another proteomic study [218]. This may be 
due to the limitations of ABE as my detection method. Future studies using other 
methods including Acyl-RAC or metabolic labeling can be helpful in confirming 
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whether PKA regulatory subunit and AC6 are indeed palmitoylated in cardiac 
cells. Another class of known palmitoylated proteins [165, 166] that I did not 
examine are β-ARs because they cannot be reliably detected using the ABE 
experimental settings as described in Chapter III. As an important technical 
consideration, I have found that the detection of palmitoylated proteins using 
ABE method is dependent on the type of detergent used to extract the proteins. 
For transmembrane proteins (such as DHHC5 in Chapter V), I found that DDM 
could not extract most of the transmembrane proteins and instead I used sodium 
dodecyl sulfate to lyse the cells before ABE.  
 The differences of protein palmitoylation between NRVM and H9c2 cells 
were more evident when we examine the rapid, stimulus-dependent 
palmitoylation of Gαs and Gαi. In Chapter IV, I concluded that H9c2 cells 
showed no significant changes in palmitoylation levels of both Gα proteins as 
well as downstream cAMP production or intracellular calcium levels. This could 
be partially explained by the lack of plasma membrane localized DHHC5 in H9c2 
cells. There are three DHHC enzymes that were previously demonstrated to be 
localized at the plasma membrane: DHHC5, 20, and 21 [70]. DHHC enzymes 
have some level of substrate redundancy [71, 262] and therefore I cannot rule 
out the presence of other DHHC enzymes in H9c2 cells that palmitoylate proteins 
at the plasma membrane. Future studies are needed to identify the expression 
and localization of these DHHC enzymes in various cardiac cells. Therefore, I 
conclude that H9c2 cells are not suitable model for studying dynamic 
palmitoylation of signaling proteins downstream of β-ARs. However, H9c2 can 
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still be useful for some preliminary studies, including identifying the palmitoylation 
sites of proteins of interest.   
 
Stimulus-dependent palmitoylation and β-AR signaling in cardiomyocytes  
 Protein palmitoylation is a common post-translational modification and the 
only reversible lipid modification. Proteomic studies suggested that at least 10% 
of the proteins encoded by the human genome are palmitoylated [188]. Protein 
palmitoylation results in various functional outcomes, including enhancing protein 
affinity to the membrane, shuttling proteins between different cellular membrane 
compartments, recruiting proteins to submembrane domains, regulating protein 
stability and protein-protein interaction (reviewed in [263, 264]). As mentioned in 
Chapter I, the recent development of non-radiolabeling methods to detect protein 
palmitoylation largely enhanced the understanding of dynamic protein 
palmitoylation and their roles in specific signaling pathways. Our group was one 
of the first to show that palmitoylation can occur with extremely rapid kinetics 
(within one minute) after extracellular stimulation, which recruits the palmitoylated 
proteins into lipid rafts to form a macromolecular complex that facilitate 
downstream signaling transduction [113]. In this study, I found a similar 
mechanism for β-AR signaling pathways in primary cardiomyocytes. 
 In Chapter III, I examined the changes in palmitoylation levels of 
endogenous proteins in primary cardiomyocytes stimulated by isoproterenol. I 
found a temporal correlation between the kinetics of Gαs and Gαi palmitoylation 
and downstream cAMP production and inotropic effects. After GPCR activation, 
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Gα proteins dissociate from the receptor and the Gβγ subunits [204]. I concluded 
that both Gαs and Gαi palmitoylation enhanced their localization to membrane 
subdomain caveolae, where the downstream effector adenylyl cyclase almost 
exclusively resides [149]. Gαs and Gαi have opposite effects on adenylyl 
cyclase. Under physiological conditions, the majority of the β-ARs in 
cardiomyocytes are coupled to Gαs. Therefore, I conclude that palmitoylation did 
not show any preference between Gαs and Gαi, but the abundance of functional 
Gαs leads to an overall positive inotropic effects. In this study, isoproterenol 
activates both Gαs-associated β1AR and β2AR, which can couple to both Gαs 
and Gαi [133]. Previous studies showed that β1AR localizes throughout plasma 
membrane while β2AR is enriched in caveolae [149]. Future studies using 
subtype-specific agonists are required to decipher whether stimulation of β1AR or 
β2AR leads to distinctive downstream palmitoylation level changes.  
 A previous study has identified a single palmitoylation site on both Gαs 
and Gαi at Cys position 3 [170]. Mutation studies in cell lines showed that 
palmitoylation of Gαs and Gαi are essential for their membrane association and 
interaction with various RGS proteins [171, 172]. My study in primary 
cardiomyocytes showed only a temporal correlation between palmitoylation and 
downstream inotropic effects. Based on a previous study using membrane 
fractionation, palmitoylated Gαi proteins are shown to be enriched in lipid raft-like 
low-density membranes [265]. Therefore I conclude that palmitoylation of Gα 
proteins in cardiomyocytes leads to their localization to caveolae. Though my 
results from the DHHC5 knockdown cells proved the importance of palmitoylation 
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in β-AR signaling, future studies using the Cys 3 mutants of Gα proteins are 
needed. Since I concluded in Chapter IV that H9c2 cells are not a fitting model to 
study agonist-induced palmitoylation, we propose that mutating the endogenous 
Gα proteins using the CRISPR-Cas9 system in beating myocytes such as the 
human stem cell derived cardiomyocytes (method established in [266]) would be 
a useful model.  
 My study also identified GRK2 as a novel palmitoylation target. Other 
members of the GRK protein family, including GRK4 [179] and GRK6 [178], have 
been shown to have multiple palmitoylation sites. However, in Chapter IV I 
showed that GRK2 likely has only one palmitoylation site. Interestingly, I only 
observe palmitoylated GRK2 after ISO stimulation in NRVM. The kinetics of 
GRK2 palmitoylation is slower than that of Gα proteins, suggesting that the 
negative feedback of the β-AR signaling occurs at later time points. A previous 
study in adult rat ventricular myocytes showed that after 5 minutes of ISO 
stimulation, GRK2 showed plasma membrane translocation [267]. This timeline is 
consistent with my observation of the increase in palmitoylation level of GRK2. 
Previous studies also suggested that GRK2 localization to the plasma membrane 
is dependent on its binding to the Gβγ subunits [162, 163]. Future work is needed 
to reveal the functional outcomes of GRK2 palmitoylation. 
My findings in Chapter III also showed that the palmitoylation levels of 
Gαs and Gαi went down while that of GRK2 remains the same after 30 minutes 
of stimulation. These findings suggest that there are enzymatic regulators that 
actively remove the palmitate moiety on both Gαs and Gαi. There are two well-
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characterized acyl protein thioesterases (APT1/2) that are responsible for the 
removal of palmitate from proteins [74-77]. Additionally, the α/β-hydrolase fold 
(ABHD) family of serine hydrolases was identified as novel depalmitoylating 
enzymes [79, 80]. APT1 has been shown to remove palmitoylation groups on 
Gαs and Gαi in vitro [76]. However, further study on the expression of APT 
proteins and ABHD proteins are required to characterize their potential cardiac 
functions and to identify which proteins are responsible for the agonist-induced 
depalmitoylation of Gα proteins.  
 
DHHC5 is a novel regulator of Gα palmitoylation and β-AR signaling in 
cardiomyocytes  
 In Chapter III, I established that DHHC5 directly palmitoylates Gαs and 
Gαi proteins and is crucial for signaling transduction downstream of β-ARs. A 
previous study showed that the Golgi-localized DHHC3 and 7 palmitoylates 
multiple Gα proteins [214]. In their study, Tsutsumi et al. first screened all 23 
mammalian DHHC enzymes by overexpressing each one of them with tagged 
Gαq, Gαs, or Gαi2 in HEK 293T cell and then observed whether there is 
increased incorporation of [3H]palmitate. Overexpression of DHHC3 and 7 
enhanced palmitoylation of all three Gα proteins, and Gαi can also be 
palmitoylated by DHHC2 and 21. However, Tsutsumi et al. focused only on Gαq 
as the palmitoylated substrate in their knockdown study and in vitro 
palmitoylation assay. Therefore, they cannot conclusively rule out the possibility 
that other DHHC enzymes can efficiently palmitoylate Gαs and Gαi.  
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 A recent study showed that one DHHC enzyme can trans-palmitoylate 
another DHHC protein and alter its activity [190]. Therefore, overexpression of 
DHHC proteins in cells lines is not an ideal method to study their direct activities 
on substrates. My study is the first to show that Gαs and Gαi are direct 
substrates of DHHC5 through an in vitro palmitoylation assay. Most of the 
previous in vitro palmitoylation assays used [3H]palmitoyl-CoA [124] or require 
purified DHHC proteins [186], I used a palmitoyl-CoA derivative conjugated to a 
dye for easy visualization of the palmitoylation signal and we used 
immunoprecipitated DHHC enzymes. I confirmed that the conjugated palmitoyl-
CoA is added to the substrate via thioester bond. Additionally, I provided 
evidence that DHHC5 has substrate specificity in my assay conditions. My 
results do not exclude the possibility that other DHHC enzymes can palmitoylate 
Gαs and Gαi. It would be interesting to test whether other DHHC enzymes, 
especially the plasma membrane localized DHHC20 and 21, are able to 
palmitoylate Gα proteins. Another limitation of my method is that there can be 
other proteins, including activators or inhibitors of DHHC5, co-precipitating with 
DHHC5 in my in vitro assay. To exclude the potential influences by co-
precipitated proteins, future studies using purified DHHC5 proteins are still 
needed. 
 In addition to palmitoylation, Gαi proteins are also myristoylated at the N-
terminus [268]. Some studies suggested that N-myristoylation is required for 
subsequent palmitoylation [269, 270]. Other studies suggested that the 
palmitoylation status of Gαi is not dependent on myristoylation [271]. My in vitro 
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palmitoylation assay results using non-myristoylated recombinant Gαi proteins 
supported the latter theory. However, given that my assay is performed without 
the presence of any membrane systems, I cannot conclusively show that the 
myristoylation and palmitoylation are two independent events in vivo.  
 In Chapter III, I showed for the first time that DHHC5 is required for the 
signaling events downstream of β-AR stimulation in primary cardiomyocytes. As 
discussed in Chapter I, previous studies on the cardiac functions of DHHC5 
focused largely on its substrate phospholemman and the subsequent massive 
endocytosis process. The existing DHHC5 hypomorphic mouse model shows 
severe cardiac developmental defects [227] and therefore may not be suitable for 
studying β-AR signaling mediated inotropic responses in physiological and 
pathological conditions.  
 A previous study in human patients with heart failure showed that 
decrease β-adrenergic responses to catecholamine is a major contributor to the 
disease [272]. It has been proposed that restoring the β-AR signaling responses 
is beneficial. For example, transgenic mice overexpressing β2AR in heart showed 
improved cardiac contractility [273]. However, prolonged activation of the β-AR 
signaling pathway is deleterious and leads to the activation of GRK-mediated 
receptor internalization (reviewed in [274]). Transgenic mice overexpressing Gαs 
showed enhanced left ventricular functions at early stages and severe 
cardiomyopathy as they age [275]. Therefore, cardiac specific and inducible 
DHHC5 deficient or overexpression transgenic animal models will be useful to 
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understand the mechanism through which DHHC5 regulates β-AR signaling in 
vivo.   
 
Palmitoylation of DHHC5 in the tail region regulates its function  
 In Chapter V, I reported that DHHC5 is palmitoylated at three Cys sites in 
the C-terminal tail. Mutation of one of the three sites is sufficient to abolish 
palmitoylation at all three sites. For many of the proteins with multiple 
palmitoylation sites including calnexin and β2AR, mutating one cysteine is not 
sufficient to abolish palmitoylation on the other site(s) [168, 216]. In the case of 
calnexin where the palmitoylation sites are adjacent (Cys 502 and 503), the 
majority of calnexin proteins are either non-palmitoylated or dual-palmitoylated, 
and mutating either site is sufficient to change protein functions [215]. My data 
suggest a similar all or none model for DHHC5 tail palmitoylation.  
 My study is the first to show that there is stimulus-dependent dynamic 
palmitoylation in the DHHC5 tail. The kinetics of DHHC5 palmitoylation are 
similar to that of Gαs and Gαi, supporting my model that palmitoylation promotes 
the spatial proximity of signaling proteins at the plasma membrane to facilitate 
efficient signaling transduction. However, to confirm whether palmitoylation 
promotes the interaction between DHHC5 and Gα proteins, or whether 
palmitoylation promotes DHHC5 localization into caveolae, future studies using 
dual-color TIRF microscopy or other complementary techniques are required. 
 It is clear from my TIRF microscopy data that palmitoylation stabilizes 
DHHC5 proteins at the plasma membrane after ISO stimulation in NRVMs. TIRF 
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microscopy has been used to study transmembrane protein dynamics after 
cellular stimulation in other studies [256-258]. For example, one study using 
Chinese hamster ovary (CHO) cells showed that γ-aminobutyric acid (GABAB) 
receptors showed increased lateral mobility after agonist stimulation, while β-ARs 
showed no such changes [257]. However, few studies have linked dynamic 
changes observed at the plasma membrane using TIRF microscopy with 
downstream signaling events. In Chapter V I showed that DHHC5Δ236-245 
mutant failed to rescue downstream cAMP production in DHHC5 knockdown 
cardiomyocytes. My data suggested that stabilization of DHHC5 at the plasma 
membrane by palmitoylation of the three Cys in the tail region is necessary for β-
AR signaling. Since there are endogenous DHHC5 proteins present when I 
examine recombinant DHHC5 tail palmitoylation, I cannot conclude whether 
DHHC5 trans-palmitoylates or is regulated by another DHHC enzyme.  
 
General conclusions and significance  
 Defects in β-AR signaling contribute to the pathogenesis of heart failure 
[276, 277]. Therefore, understanding the regulatory mechanisms of β-AR 
signaling is crucial for therapeutic intervention. S-palmitoylation is a reversible 
post-translational modification that plays an important role in regulating protein 
localization, trafficking, and stability. Multiple groups have studied the dynamic 
palmitoylation of Gα proteins in cell lines and in vitro models [120-122]. However, 
my study is the first to show that activation of β-ARs in cardiomyocytes leads to 
rapid DHHC5-mediated palmitoylation of Gα proteins to regulate contractile 
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functions (Figure 20). Mystudy also suggested that DHHC5 is an important 
mediator of myocytes contraction and a potential drug target under pathological 
conditions.  
 To date, there is no report of specific inhibitor for DHHC5 or any other 
single DHHC enzyme. The most commonly used inhibitor for palmitoylation is 2-
bromopalmitate (2-BP). 2BP is a palmitate analog that irreversibly inhibits 
multiple cellular processes including lipid metabolism [278] and S-palmitoylation 
[279]. Interestingly, it is reported that 2-BP also inhibits the depalmitoylating 
enzyme APT1 [169]. By using a click-inducible 2-BP analog, one study found that 
it does not preferentially target DHHC enzymes [280]. These studies indicate that 
2-BP is not an ideal inhibitor for protein palmitoylation. One recent study found a 
new class of compounds based on a bis-cyclic piperazine scaffold to be efficient 
and specific inhibitors for yeast Erf2 (homolog of the mammalian enzyme 
DHHC9). In the past decade, there has been growing interest in studying the 
reaction mechanisms of DHHC enzymes and the underlying structural biology 
[186], both of which are critical for the development of drugs targeting these 
proteins. Due to the potential involvement of these enzymes in a wide variety of 
pathological conditions such as cancer, cardiovascular, and neurological 
diseases, I believe that the development of inhibitors targeting specific 
mammalian DHHC enzymes is an important goal for improving human health.  
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Figure 20 Model of DHHC5-mediated palmitoylation of Gα proteins in 
cardiomyocytes  
Agonist stimulation of beta-adrenergic receptors (β-ARs) leads to palmitoylation 
(red lines) of Gα proteins and their recruitment into caveolae (grey) where they 
activate adenylyl cyclase (AC). Subsequently cAMP is produced and protein 
kinase A (PKA) is activated. PKA phosphorylates downstream substrates and 
leads to positive inotropy. DHHC5 is palmitoylated at three sites in the C-terminal 
tail. It is also phosphorylated at one (or multiple) serine(s) between amino acid 
376 and 583. Extra=extracellular; Intra=intracellular; P=phosphorylation 
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Future perspectives of palmitoylation and its enzymatic regulations 
 Protein palmitoylation is one of the most crucial post-translational 
modifications that regulate a wide variety of cellular processes in all cell types. 
Recent advances in techniques enable the discoveries of novel palmitoylated 
proteins and their palmitoylated Cys sites using proteomic approaches [109, 110, 
112, 281]. The functional outcomes of protein palmitoylation include anchoring 
cytosolic proteins to the plasma membrane, targeting proteins to membrane 
subdomains, regulating protein stability and interactions. My study and other on-
going projects from our lab aim to understand how palmitoylation of signaling 
proteins is regulated and how protein palmitoylation spatially and temporally 
coordinates with downstream events in specific cell types. Here are some of the 
major questions in the field of palmitoylation and its enzymatic regulations that 
remain to be addressed in the near future. 
 What is the physiological relevance of protein palmitoylation? With recent 
advances in genomic editing, building various tissue-specific animal models will 
be helpful in understanding the functional importance of palmitoylation. Multiple 
approaches, including mutating the palmitoylated Cys residues on target proteins 
and knocking out one (or multiple due to potential functional redundancy) of the 
DHHC enzymes, are needed to study the physiological processes regulated by 
protein palmitoylation.  
Is palmitoylation of specific subsets of proteins disrupted or enhanced in 
various diseases? Studies using well-established in vivo animal models, such as 
surgical, toxin-induced, or genetic models for heart failure, as well as human 
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patient samples are needed to determine how palmitoylation is regulated 
differently compared to normal conditions.  
 How does palmitoylation potentially affect other posttranslational 
modifications on target proteins? Many palmitoylated proteins, including Gα and 
DHHC5 in my study, undergo other types of lipidation or phosphorylation. 
However, the level of cross-talk and the regulatory mechanisms between 
palmitoylation and other modifications remain largely unsolved.   
 How are depalmitoylation enzymes regulated? Compared to the amount of 
studies on DHHC enzymes, the understanding of depalmitoylating enzymes 
APTs and ABHD proteins is still rudimentary. Future studies need to focus on the 
substrate specificity and spatiotemporal regulations of depalmitoylation enzymes. 
 My project is one of the first that studies dynamic palmitoylation of target 
proteins by a specific DHHC enzyme in cardiomyocytes. Some of the techniques 
developed in my study will be useful for future investigations of cellular functions 
of protein palmitoylation. As listed in this chapter, there are still many questions 
remain to be answered regarding the molecular, cellular, and physiological 
functions of protein palmitoylation.    
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